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Abstract 
 
 
Milk contains numerous bioactive substances including immunoglobulins, cytokines, 
growth factors and components that exert antibiotic and prebiotic activity (Field, 2005). Little is 
known about the biological effects of individual milk bioactives, despite the fact that natural 
milk improves intestinal development and immune system functions in neonates (Donovan et al., 
1994; Field, 2005) relative to milk formula.  Characterization of the biological effects of such 
components is important for optimal production of infant milk formulas to be used when 
mother’s milk is not available. Milk components with preliminary evidence of positive effects on 
the intestinal growth and mucosal immunity include osteopontin (OPN). Osteopontin is a 
phosphorylated acidic glycoprotein expressed by a number of different immune and non-immune 
cells and tissues (Sodek et al., 2000). It is also present in body fluids including blood, bile and 
milk (Sodek et al., 2000). Osteopontin is a multifunctional protein that is implicated in a wide 
number of biological processes including cell survival, bone remodeling, and immune 
modulatory functions (Sodek et al., 2000).  Furthermore, Schack and colleagues (2009) 
demonstrated that the concentration of OPN in human milk is considerably higher than in bovine 
milk and infant formulas. Taken together, it is likely that OPN plays a role in the early 
development of gastrointestinal tract and mucosal immune responses in infants. Since the 
neonatal pig shares anatomical, physiological, immunological, and metabolic similarities with 
the human infants (Moughan, et al., 1992), they were selected as the animal model in our studies. 
Our first aim was to investigate the effects of OPN on piglet intestinal development. 
Newborn, colostrum-deprived piglets (n=27) were randomized to receive three treatments: 
formula with bovine OPN (OPN; 140 mg/L); formula alone (FF); or sow reared (SR) for 21 
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days. Body weight, intestinal weight and length, mucosal protein and DNA content, 
disaccharidase activity, villus morphology, and crypt cell proliferation were measured. Statistical 
significance was assigned at P<0.05. No significant effects of OPN were observed for body 
weight, intestinal weight and length. Mucosal protein content of SR piglets was lower than FF 
and OPN piglets in the duodenum, but higher than FF and OPN piglets in the ileum. No 
significant effects of diet in mucosal DNA content were detected for the three regions of the 
small intestine. Lactase and sucrase activities of SR piglets were higher than the two formula-fed 
groups in the duodenum, lower in the ileum. No significant  effects of diet on lactase and sucrase 
activities were noted between two formula-fed groups in the duodenum and ileum. Jejunal 
lactase activity of FF piglets was higher than SR piglets, whereas no significant effect of diet was 
observed in jejunal sucrase activity among the three groups. Duodenal and ileal villus height and 
villus area of SR piglets were lower than two formula-fed groups, while OPN piglets did not 
differ from FF piglets. There was a significant effect of diet (P<0.0001) on jejunal crypt cell 
proliferation, with proliferation in OPN piglets being intermediate between that of FF and SR.  In 
summary, supplemental OPN increased jejunal crypt cell proliferation, independent of evident 
morphological growth, and had a minor impact on disaccharidase activity in the small intestine 
of neonatal piglets. 
Rotavirus (RV) is the most common viral cause of severe gastroenteritis in infants and 
young children worldwide (Parashar et al., 2006).  Maeno et al. (2009) reported that OPN 
knockout (OPN-KO) suckling mice were more susceptible to RV infection compared to wild-
type (WT) suckling mice. To detect the role of OPN in intestinal immune responses of neonates, 
the goal of the second study was to evaluate whether supplemental OPN influenced the serum 
antibody responses to RV vaccination in neonatal piglets. Newborn, colostrum-deprived piglets 
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were randomized into two dietary groups: formula with bovine OPN (OPN; 140 mg/L) and 
formula alone (FF) for 35 days. On d7, piglets in each dietary group were further randomized to 
receive rotavirus (RV) vaccination (Rotarix®) (FF+RV and OPN+RV) or remained non-
vaccinated (FF+NV and OPN+NV). Booster vaccination was provided on d14. Blood samples 
were collected on d7, 14, 21, 28 and 35. RV-specific serum immunoglobulin (Ig) G, IgA, IgM 
and total serum IgG, IgA, IgM were measured by ELISA. Statistical significance was assigned at 
P<0.05, with trends reported as P<0.10. Body weight gain was unaffected by diet and/or 
vaccination. No significant effect of oral OPN supplementation was observed for RV-specific 
antibody responses and total Igs levels. After the combination of dietary groups, RV piglets had 
significantly higher RV-specific IgM concentrations compared to NV piglets. Although there 
were higher means of RV-specific IgG and RV-specific IgA concentrations in RV group than 
their counterparts in NV group, the difference did not reach statistical significance. RV-specific 
IgM reached a peak at d7 post booster vaccination (PBV), whereas the RV-specific IgG and IgA 
peaked later at PBV 14 or 21. Total Igs were unaffected by RV vaccination but were 
significantly increased over time, following similar pattern as RV-specific Igs. In summary, 
neonatal piglets generated weak antibody responses to RV vaccination. Supplemental OPN did 
not enhance RV-specific serum antibody responses and total serum Igs levels in neonatal piglets 
with or without RV vaccination.   
In conclusion, we observed normal developmental changes in the small intestine and 
serum Igs levels in neonatal piglets over time. Oral OPN supplementation showed minimal 
impacts on intestinal development and no effect on serum Igs levels. The role of supplemental 
OPN on the growth and development of infants is still inconclusive. Future studies should 
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measure other physiological and immunological parameters by using different models of 
vaccination or infection.  
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Chapter 1 
Literature Review 
1.1 Osteopontin 
Osteopontin (OPN) was first described as a secreted, 60-kDa transformation-specific 
phosphoprotein (Senger et al.1979) and subsequently was rediscovered by molecular cloning of 
the transformation-associated gene 2ar (Craig et al., 1989). The name “osteopontin” was 
introduced to reflect the potential of the bone protein to serve as a bridge between cells and 
hydroxyapatite through RGD and polyaspartic acid motifs discovered in the primary sequence of 
the protein (Oldberg et al., 1986). However, the same gene product was identified as a putative 
lymphokine produced by activated lymphocytes and macrophages and called Eta-1 or early T-
lymphocyte activation gene I (Palarca et al., 1989), and, thus, a more general pattern of 
expression for OPN was emerging. Accordingly, secreted phosphoprotein (SPP 1) was 
introduced as an alternate name, to reflect a broader functional role of this protein.  
 
Structural Characteristics 
The functional motifs of the OPN molecule, illustrated in Figure 1.1 (Wang & Denhardt, 
2008), may provide clues to OPN’s broad biological functions. OPN is expressed by a single-
copy gene, in a cluster of SIBLING (Small Integrin-Binding Ligand, N-linked Glycoprotein) 
family proteins, as a ~34 kDa nascent protein that is extensively modified by posttranslational 
events. The human gene contains 7 exons, spans ~11.1 kb, and maps to the long arm of 
chromosome 4 (4q13) (Young et al., 1990). In comparison, the ~4.8 kb mouse gene is at the 
locus of the Rickettsia resistance gene Ricr on chromosome 5 (Miyazaki et al., 1989), and the pig 
gene is on chromosome 8 (Denhardt and Guo, 1993).  
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The expression of OPN is affected by a large number of hormones, cytokines, and growth 
factors that can influence the rate of gene transcription, mRNA processing, stability and 
translation, as well as post-translational modifications. Increased expression of OPN is 
frequently associated with an increase in transcription of the OPN gene, which is regulated by 
transactivation of cis-acting elements in the gene promoter. Its promoter is responsive to a 
number of different transcription factors (Denhardt et al., 2003). Pro-inflammatory cytokines 
stimulate OPN gene transcription and expression. For example, activation of macrophages with 
lipopolysaccharide (LPS) and nitric oxide (NO) induces OPN gene expression and protein 
secretion (Mazzali et al., 2002). Classical mediators of acute inflammation such as tumor 
necrosis factor alpha (TNF-α) and interleukin-1beta (IL-1β) strongly induce OPN expression 
(Patarca et al., 1993). Additional factors that can up-regulate OPN expression include 
angiotensin II, transforming growth factor-beta (TGF-β), hyperglycemia and hypoxia (Ricardo et 
al., 2000; Hullinger et al., 2001; Sodhi et al., 2001).  
Full-length OPN is composed of about 300 amino acids (297 in mouse; 314 in human); 
there are also functionally important cleavage products and occasional splice variants. Although 
expressed as a ~34 kDa nascent protein, extensive posttranslational modifications increase its 
apparent molecular weight to about 44 kDa; in SDS-PAGE gels it migrates in the range of 50~75 
kDa depending on conditions (Sodek et al., 2000). Both highly conserved sequence motifs and 
post-translational modifications contribute to different functional activities of OPN (Kazanecki et 
al, 2007). 
The protein is rich in aspartic and glutamic acid and serine residues, and contains a 
polyaspartic acid motif, through which the protein can bind to hydroxyapatite and calcium ions, 
and an arginine-glycine-aspartate (RGD) sequence that can mediate cell attachment. In addition, 
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multiple sites of Ser and Thr phosphorylation and sites of both N- and O-linked glycosylation 
exist, together with a thrombin cleavage site. Variations in phosphorylation, glycosylation, and 
sulphation generate different functional forms of OPN which may be found in the same or 
different tissues. 
 
Amino Acid sequence comparisons 
The amino acid sequences of OPNs derived from human (Kiefer et al., 1989), cow (Kerr 
et al., 1991), pig (Wrana et al., 1989), rabbit (Tezuka et al., 1992), rat (Oldberg et al., 1986), 
mouse (Craig et al., 1989), and chicken (Moore et al., 1991 ) cDNAs are currently available. 
Comparison of the mammalian OPN sequences reveals a high conservation in the amino- and 
carboxy-terminnal regions and in the polyaspartate segment, as well as in the GRGDS and 
thrombin cleavage sites and in several potential phosphorylation sites (Figure. 1.2). Of the 333 
amino acids in the consensus sequence for mammalian OPNs (CLUSTAL W program, 
Thompson et al., 1994), 107 amino acids are identical, with 59 amino acids retaining high 
similarity and a further 26 with lower similarity, for a conservation of 58% of the amino acids. 
Notably, there is also high identity (10/21 residues identical) in a sequence (220-240) that is 
missing in bovine OPN and in a short sequence (312-316) that is missing in both the cow and the 
pig (Sodek et al., 2000). When the avian sequence is included in the comparison, the number of 
perfect matches is reduced considerably, to 52, with 48 amino acids retaining high similarity and 
37 with lower similarity, for a conservation of 39% (Sodek et al., 2000). Despite the reduced 
conservation, the GRGDS motif, the polyaspartic acid sequence, and the thrombin cleavage sites 
are retained, together with several phosphorylation sites (Sodek et al., 2000). Nevertheless, 
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distinct differences in the developmental expression have been reported which could reflect 
functional differences between chicken and mammalian OPNs (Thayer and Schoenwolf, 1998). 
 
Structure-Function Analysis 
Cell Attachment and Signaling through Integrins. As shown in Figure 1.1 (Wang & 
Denhardt, 2008), located near the center of the OPN protein is a RGD domain, a motif common 
to many extracellular matrix proteins and known to engage many integrins. The protein also 
contains an aspartate-rich region, two heparin-binding sites, a thrombin cleavage site and a 
region near the C-terminus that binds specific CD44 variants. Via the RGD sequence, OPN 
interacts with a variety of cell surface receptors, including the αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 
(O’Regan & Berman, 2000; Yokosaki et al., 2005). A cryptic integrin binding site is exposed 
after thrombin cleavage between the L and R residues; it is important in the regulation of cell 
adhesion, spreading and migration by promoting the adherence of cells expressing α4 and α9 
integrins (α9β1, α4β7), which are preferentially expressed by leukocytes (Helluin et al., 2000). 
Both intact OPN and the N-terminal fragment of OPN promote leukocyte adhesion to α4β1; 
interestingly, there are two different binding sites for α4β1 present in a 38-amino acid domain 
within the N terminal thrombin fragment (Bayless et al., 1998). The interaction of OPN with the 
α8β1 integrin is necessary for normal kidney morphogenesis (Denda et al., 1998). 
Cell Attachment and Signaling through CD44. OPN interacts with CD44v6- and v7-
containing isoforms, stimulating (in a human tumor cell) transcription of the CD44 gene and also 
the abundance of CD44s, v6 and v9 at the cell surface (Khan et al., 2005). The interaction of 
OPN with CD44 appears to be RGD-independent and to require the presence of β1 integrins 
(Katagiri et al., 1999). The ligation of CD44 variant isoforms by OPN mediates chemotaxis and 
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adhesion of fibroblasts, T cells and bone marrow cells (Denhardt et al., 2001; Wai et al., 2004). 
CD44 engagement with OPN down-regulates IL-10 expression in peritoneal macrophages 
(Ashkar et al., 2000). OPN promotes proliferation and survival of IL-3-dependent bone marrow 
cells; anti-CD44 antibody attenuates these actions (Lin et all, 2000). A C-terminal location has 
also been suggested as the site of CD44 interaction (He et al., 2006). A monoclonal antibody 
recognizing the C-terminal region of OPN blocked the ability of OPN to attach to cells, raising 
the possibility that attachment of OPN to CD44 modulates the cells’ ability to bind to the RGD 
binding motif via the RGD sequence (Kazanecki et al., 2007). Kazanecki et al. (2007) have 
hypothesized that a sequence in the C-terminal region forms a β-sheet structure with the 
RGDSVVYLGR domain, thereby interfering with the RGD-integrin interaction. 
 
Post-translational Modifications (PTM) of Osteopontin 
The PTM of OPN influences its function (Kazanecki et al., 2007). The OPN protein is 
highly modified, including Ser/Thr phosphorylation, O-linked glycosylation, tyrosine sulfation 
and sialylation. Many sites of PTMs are conserved across species; however, the degree of 
modification of the protein varies depending on the source tissue and cell type or differentiation 
stage. For example, both bovine and human milk OPN have a large number of phosphorylated 
serine residues (28 and 32, respectively, mostly in motifs implicating casein kinase 2). These are 
located in clusters (Figure 1.1, Wang &  Denhardt, 2008) that are distant from the RGDSVVY 
and glycosylated regions (Christensen et al., 2005, 2007). In contrast, rat bone OPN contains 
only 10-11 phosphorylated residues (Keykhosravani et al., 2005). Phosphorylation of OPN 
appears necessary for various physiological functions, including migration of cancer cells (Al-
Shami et al., 2005), adhesion and bone resorption by osteoclasts (Razzouk et al., 2002), 
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inhibition of smooth muscle cell calcification (Jono et al., 2000) and regulation of mineralization 
(Gericke et al., 2005). The phosphorylation of OPN is usually heterogeneous, and it is not known 
whether certain specific sites are critical for a given function. 
 
Tissue Distribution 
Osteopontin is expressed in a variety of tissues, such as bone, kidney, brain, vascular 
tissues, brain cells and specialized epithelia found distal renal tubules and in the gut, as well as in 
activated macrophages and lymphocytes (Sodek et al., 2000). Osteopontin also appears in 
biological fluids, including blood, milk, urine and seminal fluid (Sodek et al., 2000).  The 
amount of OPN in normal plasma of women ranges from 22 to 122 µg/L, with a median level of 
47 µg/L (Singhal et al., 1997), whereas in urine, OPN ranges from 1.9 to 4.3 µg/mL, with ~4 mg 
excreted per day (Min et al., 1998). In milk, OPN is present as an intact protein or in several 
proteolytically generated N- and C-terminal fragments (Sørensen et al., 2003). 
Osteopontin is found in a restricted distribution in healthy adult humans and animals, 
whereas studies of OPN in disease and injury have revealed striking up-regulation under 
conditions of inflammation and tissue remodeling (Giachelli et al., 2000). Thus, OPN synthesis 
is induced in smooth-muscle cells and cardio-myocytes in cardiovascular diseases, including 
atherosclerosis (Giachelli et al., 1993) and ventricular hypertrophy (Graf et al., 1997). Similarly, 
OPN is induced in kidney diseases, such as interstitial nephritis (Sibalic et al., 1997) and in 
pathological mineralization such as kidney stone formation (McKee et al., 1995). Synthesis of 
OPN by activated lymphocytes and macrophages (Patarca et al., 1989, 1993) can account for the 
presence of OPN in diseased and damaged tissues. Studies on granulomatous inflammation have 
indicated that, as well as acting as a chemoattractant for T-cells, OPN can promote adhesion of 
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T-cells and possibly amplify a CD3-mediated proliferative response (O'Regan et al., 1999). The 
increased OPN activity following thrombin digestion observed in these studies suggests a 
mechanism whereby OPN and thrombin can modulate T-cell recruitment and activation. All of 
these situations have in common an inflammatory component, leading investigators logically to 
study the potential role of osteopontin in host defense responses. 
 
Signaling Pathways of Osteopontin 
As depicted in in Figure 1.3 (Wang &  Denhardt, 2008), OPN can signal through several 
different pathways to affect gene transcription.  OPN signaling through integrins can modulate 
(via activation of Ras and Src) the phosphorylation of kinases (NIK, IKKβ) involved in nuclear 
factor kappa-B (NFκB) activation (Rice et al., 2006; Scatena et al., 1998); this results in the 
degradation of IκB, an inhibitor of NFκB (Vejda et al., 2005). NFκB regulates expression of 
many inflammatory cytokines. Consequently, OPN may modulate immune responses through 
activation of the NFκB pathway, and the absence of OPN may be associated with diminished 
cytokine functionality. In a study of the role of OPN in the exacerbation of experimental 
autoimmune encephalomyelitis, it was observed that OPN appeared to enhance the survival of 
myelin-reactive T cells through the regulation of the transcription factors Foxo3a and NFκB and 
the expression of genes involve in apoptosis (Hur et al., 2007).  
In addition, OPN signaling through CD44 engagement promotes cell survival by 
activating the PI3K/Akt pathway (Lin et al., 2001). A genetic profiling study documented that 
OPN is a downstream effector of the PI3K/Akt pathway, which is antagonized by phosphatase 
and tensin homolog (PTEN); melanoma lines defective in PTEN expression exhibited increased 
OPN expression (Packer et al., 2006). Lastly, in the presence of viral infections, intracellular 
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OPN is found to be localized together with the MyD88 and TLR9 complex near the inner 
cytoplasmic membrane; it activates nuclear translocation of transcription factor IRF7 to induce 
robust IFN-a production (Shinohara et al., 2006).  
 
Osteopontin and Innate Immunity 
Most infectious agents induce inflammatory responses by activating innate immunity in 
processes often involving macrophages and neutrophils. These cells are the professional 
phagocytes that provide the first line of defense of the immune system. Epithelial damage causes 
release of the cytokines IL-1 and IL-8, which recruit macrophages and neutrophils to the site of 
injury (Wang et al., 2008). Macrophages express toll like receptors that recognize pathogen-
associated molecular patterns (PAMPs) and engulf the pathogen, leading to the secretion of 
cytokines/chemokines that attract cells such as neutrophils and monocytes to sites of injury or 
infection (Wang et al., 2008). The role of OPN in innate immunity is reflected in its protective 
function in infectious diseases. It contributes to the mucosal defense against viral pathogens. 
Significant up-regulation of OPN mRNA in murine intestine and epithelial cells was observed in 
rotavirus infection, and the disease was protracted in OPN-deficient mice (Rollo et al. 2005). 
Likewise, OPN deficient mice are impaired in their ability to clear Listeria monocytogenes after 
systemic infection (Ashkar et al., 2000). Figure 1.4 (Wang &  Denhardt, 2008) illustrates aspects 
of the involvement of OPN in innate and adaptive immune functions.  
 
Osteopontin and Macrophages 
Monocytes express a low level of OPN, but as they differentiate into macrophages OPN 
expression is increased; OPN becomes constitutively expressed in macrophages and can be 
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further up-regulated by LPS stimulation (Gao et al., 2004). In addition, OPN has been shown to 
regulate macrophage functions including migration (Zhu et al., 2004), activation (Rollo et al., 
1996), phagocytosis (McKee & Nanci, 1996), proinflammatory cytokine production (Koguchi et 
al., 2002) and nitric oxide synthesis (Scott et al., 1998) in response to various inflammatory 
challenges. In the absence of OPN expression, macrophage migration and cytokine production 
are impaired (Sodek et al., 2006). At sites of tissue injury, OPN produced by macrophages 
fosters cell adhesion and may act as an opsonin facilitating phagocytosis of foreign bodies 
(McKee & Nanci, 1996). The interaction of OPN with integrins and CD44 (v) stimulates via 
different signal transduction pathways distinct patterns of cytokine/ chemokine expression and 
the specific immune response (Wang & Denhardt, 2008). 
. 
Osteopontin and Dendritic Cells 
Dendritic Cells (DCs) are a type of unique immune cell population that functions as a 
link between innate and adaptive immunity. They function as effector cells in the innate immune 
system to provide the first line of defense by non-specifically recognizing invading pathogens. 
Through maturation and migration from the sites of infection towards secondary lymphoid 
organs, they turn into professional antigen-presenting cells to induce antigen specific T cell 
activation. Osteopontin is highly expressed in immature DCs, but its production decreases during 
maturation (Kawamura et al., 2005). As observed for other inflammatory cells, OPN is also a 
survival factor for DCs (Kawamura et al., 2005). Osteopontin-activated DCs produce IL-12 and 
TNF-α, and, when incubated with naive T cells, can induce naive T cells into Th1-polarizing, 
interferon-gamma (IFN--producing T cells (Renkl et al., 2005). Thus, OPN’s presence in T 
cell-DC interactions may decisively influence T-cell polarization. This concept is emphasized by 
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the deficiency of Th1 immunity in OPN deficient mice, which leads to a compromised host 
defense against bacterial and viral infections (Rollo et al., 2005) and ameliorated autoimmunity 
(Chabas et al., 2001). 
 
Osteopontin and Cell-Mediated Immunity 
Osteopontin is considered to be an important lymphocyte mediator that is secreted by 
activated T-lymphocytes.  It induces macrophage migration and suppresses the production of 
reactive oxygen species, while enhancing immunoglobulin production and proliferation of B-
lymphocytes (Weber & Cantor, 1996). Osteopontin was shown to be required for cell-mediated 
immunity and the development of the Th1 pathway and macrophage activity (Ashkar et al., 
2000). 
Elevated OPN expression is found in various immunological disorders. Up-regulation of 
OPN is implicated in the formation of granulomas in tuberculosis, sarcoidosis and silicosis, all of 
which involve cell-mediated immune reactions (Nau et al., 1997). Studies of OPN null (OPN−/−) 
mice revealed that OPN’s main immune-modulatory function is the enhancement of Th1 over 
Th2 immunity through two general mechanisms: regulation of cytokine production via 1) 
interaction with the αvβ3 integrin to induce pro-inflammatory IL-12, and 2) ligation of CD44v to 
suppress anti-inflammatory cytokine IL-10 production (Ashkar et al., 2000). Autocrine 
amplification of cytokine production and cross-inhibition ensure progressive polarization of the 
T-helper cells towards either Th1 or Th2 cells (Abbas et al., 1996).  
Osteopontin is produced by activated T cells and is classified as a Th1 cytokine because 
it modulates cell-mediated immunity by promoting the Th1 response. In T-helper (CD4+) T-cells, 
OPN mRNA is expressed in Th1 polarized cells (Nagai et al., 2001). Moreover, soluble OPN 
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may modulate the differentiation and proliferation of CD4+ and CD8+ (cytotoxic) T cells 
(Higuchi et al., 2004). OPN can also stimulate human peripheral blood T cells to express IFN-γ 
and CD40L, which subsequently induce IL-12 expression from monocytes; up-regulation of 
CD40L by OPN in T-lymphocytes (O'Regan and Berman, 2000) provides mechanistic support 
for the association of OPN with polyclonal B-cell proliferation and humoral autoimmune disease 
(Weber et al., 1996). Furthermore, the increase of OPN levels was inversely correlated with in 
vitro T-cell IL-10 production. Osteopontin regulates cell-mediated immunity by promoting T cell 
proliferation and migration as demonstrated in transgenic mice over-expressing OPN (Wang & 
Denhardt, 2008).  While OPN is generally classified as a pro-inflammatory cytokine, it appears 
to have anti-inflammatory effects in certain pathological contexts. The multifunctional nature of 
OPN may reflect expression of specific isoforms, levels or timing of production and tissue 
distribution (Wang &  Denhardt, 2008). Dual (pro- vs. anti-inflammatory) effects of OPN in 
intestinal inflammation have been reported. During the acute phase of colitis, OPN seems to 
activate innate immunity, reduce tissue damage and initiate, mucosal repair whereas during 
chronic phase it promotes the Th1 response and promotes inflammation (Heilmann et al., 2009).  
 
Osteopontin and Mucosal Protection 
 Determinants of Mucosal Immunity. A specialized epithelial barrier lining the oral cavity, 
the intestinal tract, respiratory tract, and urogenital systems provides the primary protection for 
mucosal tissues against pathogens and other environmental insults. Breakdown of the barrier 
function leads to the infiltration of bacteria or luminal noxious agents that cause inflammatory 
diseases, including periodontal disease in the oral cavity, inflammatory bowel diseases (IBDs) 
(Tlaskalova-Hogenova et al., 2004), respiratory diseases (Delclaux & Azoulay, 2003) and 
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urogenital diseases (Mulvey, 2002). Physical protection is achieved by the formation of tight 
junctions connecting the epithelial cells, while goblet and other specialized secretory cells 
produce mucous enriched with antimicrobial glycoproteins, IgA class antibodies, cytokines, and 
chemokines to defend against the invasion of pathogens and maintain the integrity of the 
epithelial barrier (Acheson & Luccioli, 2004). Another aspect of this barrier is the viscosity of 
the mucous secreted by the epithelial cells, which can prevent the adherence of particles or 
micro-organisms that are otherwise expelled by ciliary movement in the respiratory tract, or by 
peristalsis in the gut. Failure of these barrier functions may lead to recurrent respiratory tract 
infections or infestation and infection of the gut lumen, respectively (Sodek et al., 2006). 
Noxious irritation/damage of the epithelial barrier can be mediated by epithelial cells through 
special recognition receptors such as death Toll-like receptors, by specialized epithelial cells 
(microfold; M-cells), or, more directly, by the penetration of bacteria or their products (Shi & 
Walker, 2004). Penetration of the epithelial barriers results in activation of resident neutrophils 
(polymorphonuclear leukocytes; PMNs) and macrophages; these are professional phagocytes, 
which provide the "immediate innate immune response" and non-specifically engulf foreign 
material and bacteria (Figure 1.5A, Sodek et al., 2006). Cytokines and chemokines released 
from the injured epithelium as well as the leukocytes increase neutrophil and macrophage 
infiltration into the tissue, and thereby initiate the inflammatory response (Sodek et al., 2006). 
Long-term residents of the subepithelial tissue, the antigen-presenting cells (APC)/dendritic cells, 
which are specialized macrophages, initiate the more specific "adaptive immune responses". The 
adaptive system is based on a specific recognition between APC and naive T-cells, resulting in 
the differentiation of Th1, T-helper, and cytotoxic (NKT) T-cells, which control the immune 
reaction (Figure 1.5B, Sodek et al., 2006). Notably, many studies have correlated OPN 
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expression with epithelial barrier changes (Gassler et al., 2002), with macrophage (O'Regan et al., 
2001; Zhu et al., 2004), neutrophil (Alstergren et al., 2004), and lymphocyte activities (Ashkar et 
al., 2000), and with the function of reparative fibroblasts (Sodek et al., 2002). 
 
Osteopontin and the Epithelial Barrier Function. Osteopontin has been recognized as an 
important luminal regulator (Brown et al., 1992), due to its expression by epithelial cells 
covering luminal cavities capable of active secretion and absorption of nutrients or gasses. 
Indeed, earlier studies showing that epithelial cells secrete OPN first indicated that OPN is 
involved in controlling epithelial barrier permeability and secretory functions (Butler, 1989). In 
the gastrointestinal tract, a layer of columnar epithelial cells separates the underlying mucosa 
from the lumen and provides a reservoir for macrophages and T- and B-lymphocytes, which are 
concentrated in an organized subepithelial network along the gut and can be identified in focal 
areas, such as the Peyer's patches in the distal small intestine (Sodek et al., 2006). Moreover, the 
epithelial layer also contains specialized cells, such as the microfold (M) cells, capable of 
recognizing specific bacteria and antigens and transferring them to specialized APCs that reside 
in the vicinity of the epithelial layer, and take part in the initiation of the adaptive defense 
process  (Mowat, 2003; Acheson & Luccioli, 2004) (Figure 1.5, Sodek et al., 2006). The MHC 
class-II and Toll like receptors on specialized epithelial cells may be involved directly with 
antigen presentation to underlying CD4+ T-cells (Acheson & Luccioli, 2004) (Figure 1.5, Sodek 
et al., 2006). It has been suggested that the constitutive expression of OPN by epithelial cells is 
required for maintaining the epithelial barrier in the intestines (Gassler et al., 2002). OPN also 
has the potential to regulate specific functions of epithelial cells involved in the barrier defense 
process (Figure 1.5, Sodek et al., 2006), such as the expression of MHC-II and Toll receptors, 
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which aid in antigen presentation and inflammatory signaling (Mowat, 2003; Iwasaki & 
Medzhitov, 2004). 
The ability of the epithelial barrier to resist stress and trauma, and to regenerate, is 
important for the subsequent repair of the diseased tissues. Death of epithelial cells, therefore, is 
an important event associated with mucosal damage (Hagimoto et al., 2002; Kruidenier et al., 
2003). In view of the role of OPN in cell survival, its presence may be important for supporting 
programmed cell death and preventing rapid necrotic death, which can result in intense 
inflammation and loss of epithelial barrier and protection (Sodek et al., 2006).  
 
Osteopontin and Biomineralization 
As mentioned earlier, OPN is highly expressed in mineralized tissues including bone and 
teeth. In fact, it is one of the most abundant non-collagenous proteins in bone (Giachelli & Steitz 
2000). Furthermore, OPN is also invariably found in pathological calcifications of soft tissues. 
The association of OPN with biomineralization has led to a great number of studies aimed at 
elucidating its function in this process. At least three different functions of OPN in calcified 
tissues have been proposed based on in vitro and in vivo findings: 1) regulation of bone cell 
adhesion; 2) regulation of osteoclast function; and 3) regulation of matrix mineralization 
(Giachelli & Steitz, 2000).  
 
Osteopontin and Cell Survival 
 Osteopontin is a cell survival factor. Both soluble OPN, which works as a cytokine, and 
immobilized OPN, which function as an extracellular matrix protein, protect against apoptosis 
and induce survival and proliferation in several cell types (Standal et al., 2004). Several in vitro 
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studies have reported that OPN has a pro-survival and/or proliferative function in adherent cell 
types such as smooth muscle cells (Weintraub et al., 2000) and epithelial cells (Elgavish et al, 
1998). Liu et al. (2009) reported that the overexpression of OPN in human embryo kidney-293 
cells significantly increased the level of cell proliferation in vitro. Furthermore, despite 
diminished macrophage infiltration and interstitial fibrosis, the obstructed kidneys of OPN 
knockout mice exhibit increased levels of tubular cell apoptosis compared to wild-type mice, 
suggesting that OPN is capable of providing survival signals to tubular epithelial cells in vivo 
(Ophascharoensuk et al., 1999). The binding of OPN to the αvβ3 integrin of endothelial cells 
activates the pro-survival transcription factor NFκB and protects endothelial cells from 
undergoing apoptosis (Scatena et al., 1998).  
 
Osteopontin and Tumorigenesis 
Osteopontin is strongly associated with tumorigenesis (Standal et al., 2004). In patients 
with breast cancer (Singhal et al., 2004), multiple myeloma and prostate cancer (Saeki et al., 
2003), high plasma levels or tumor expression of OPN are associated with poor prognosis. OPN 
is expressed by several types of cancer cells (Standal et al., 2004; Ue et al., 1998). Some of them 
also respond to OPN with enhanced survival and proliferation. A study indicated that epidermal 
growth factor (EGF) dependent proliferation of prostate cancer cells is amplified by OPN 
(Angelucci et al., 2004). This is probably due to an interaction of OPN with beta1 integrins on 
the surface of the cancer cells, leading to sustained activation of the epidermal growth factor 
receptor (EGFR) (Standal et al., 2004). Epidermal growth factor (EGF) is an important growth 
factor for prostate cancer cells and this interaction thereby promotes proliferation of the cancer 
cells. Similarly, IL-6 is an important growth promoting/survival factor for myeloma cells, and 
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OPN has been shown to promote myloma cell growth in combination with IL-6 (Standal et al., 
2004).  Receptors involved are α4β1 and αvβ3 (Abe et al., 2004) but the precise molecular 
mechanisms are currently not known. Although cancer cells often produce OPN, they also give 
rise to enhanced OPN production by host cells such as stromal cells/osteoblasts (Hullinger  et al., 
2000; Standal et al., 2004) and osteoclasts (Abe et al., 2004). OPN effects on tumor cells can 
thus be both autocrine and paracrine. Autocrine effects can influence cell proliferation and 
survival, converting benign tumor cells into highly metastatic cells (Oates et al., 1996), whereas 
paracrine effects can provide protection from cytotoxic macrophages, possibly by inhibiting the 
production of nitric oxide (Denhardt and Chambers, 1994). Collectively, these mechanisms could 
explain how tumor cells not expressing OPN are eliminated, while providing a mechanism of 
tumor cell escape and selection of OPN-producing clones in secondary metastases (Crawford et 
al., 1998). In this regard, higher median levels of plasma OPN in metastatic breast cancer have 
been associated with increased tumor burden and decreased survival (Singhal et al., 1997). 
 
Osteopontin and Infant Nutrition 
Milk is an excellent source of nutrient (energy, macronutrients, vitamins and minerals) as 
well as bioactive proteins that play important roles in infant immunity. During the first phase of 
life, when infants are immunologically immature, breastfeeding provides an effective protection 
against infections (Lawrence & Pane, 2007); breast-fed infants have a reduced frequency of 
infectious episodes compared with formula-fed infants (Huffman & Combest, 1990; Dewey et al., 
1995). This protective effect of human milk is likely achieved through the numerous bioactive 
components contained in the milk, which include proteins and peptides with antimicrobial and 
immune-stimulating properties such as lactoferrin, lactoperoxidase, lysozyme, and IgA (Hanson 
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et al., 2003; Field, 2005). However, a significant protein compositional dissimilarity exists 
between human milk and that of bovine milk and infant formulas (Hambreus et al., 1977). A less 
well-characterized bioactive protein that could potentially play a role in neonate and infant 
immunity and development is OPN. 
As noted earlier, OPN is present in most tissues and body fluids, with the highest 
concentrations being found in human milk. Schack and his colleagues (2009) measured and 
compared OPN concentration in human milk, bovine milk, and infant formulas by enzyme-
linked immunosorbent assay (ELISA). The OPN concentration in human milk was 
approximately 138 mg/L, which was considerably higher than the corresponding OPN 
concentrations in bovine milk (~18 mg/L) and infant formulas (~9 mg/L). The OPN levels in 
plasma from 3-months-old infants and umbilical cords were found to be 7 to 10 times higher than 
in adults (Schack et al. 2009). Moreover, isolated bovine milk OPN was shown to induce the 
expression of the Th1 cytokine IL-12 in cultured human lamina propria mononuclear cells 
isolated from intestinal biopsies (which represent the first line of the immune system at the gut 
mucosal surface) (Schack et al. 2009). Thus, the intestinal immune system may be modulated by 
ingested OPN. This is further supported by the observation that bovine and human milk OPN 
was resistant to proteolysis by neonatal gastric juice at pH 4.0 and above (Chatterton et al., 2004). 
Mean gastric pH has been reported to rise shortly after feeding in infants fed human milk, 
reaching pH values of 6.4 within 30 min after a bolus of human milk, gastric pH subsequently 
decreasing with time (Mason, 1962). Thus, part of the ingested OPN survives the passage 
through the infant’s stomach and reaches the immune cells present in the intestine. The ingested 
OPN might further act directly against pathogenic bacteria in the gastrointestinal tract; OPN was 
able to opsonize bacteria, which leads to an enhanced phagocytosis (Schack et al., 2009). In a 
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recent study using preterm piglets, OPN enrichment decreased necrotising enterocolitis (NEC) 
severity relative to control formula, without any significant effects on intestinal morphology and 
digestive enzyme activities (Møller et al., 2011). Supplementation of infant formula with OPN 
could therefore potentially provide the infant with an important immunological factor. 
 
1.2 Rotavirus and Rotavirus Vaccine 
 
Epidemiology of Rotavirus Gastroenteritis 
Among children in both the developed and developing world, rotavirus (RV) is the most 
commonly identifiable agent (Kapikian, 1993). In both the developed and developing world, it 
accounts for 25-50% of gastroenteritis requiring hospitalization in pediatrics (Bresee, 2008). 
Rotavirus gastroenteritis occurs almost exclusively in infants and children, with nearly every 
child having been infected by the age of 5 years (Bernstein, 2009). The majority of serious 
infections occur between 4 and 24 months of age (Podewils et al., 2004). Older children are 
protected from serious disease by previous exposure and apparent infection. Similarly, disease 
can occur in neonates, but is typically mild or asymptomatic due to protection from maternal 
antibodies (Glass et al., 2009).  
 
Biology of Rotavirus 
Rotaviruses are non-enveloped viruses of the genus Reoviridae (Martella et al., 2010). 
The virus is characterized by a double-stranded RNA genome composed of 11 segments, which 
encode for six viral structural (VP) and six nonstructural proteins (NSP) (Greenberg et al., 2009; 
Martella et al., 2010). Rotavirus particles are icosahedrons, 70–75 nm in diameter, composed of 
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three concentric layers of structural proteins: the core, an inner capsid, and an outer capsid 
(Figure 1.5, Jayaram et al., 2004). The outer capsid is composed of a viral protein 7 (VP7) 
coating with VP4 spikes protruding from the viral surface (Greenberg et al., 2009). This layer is 
the most antigenically important portion of the virus, with the VP7 glycoprotein (G-type antigen) 
and VP4 protease-sensitive protein (P-type antigen) being the major immunological targets of the 
human immune system (Greenberg et al., 2009). The inner capsid is composed solely of VP6. 
Based on the antigenic properties of VP6, rotaviruses are broken into 7 serogroups, denoted A–G. 
Serogroup A is the only serogroup that commonly causes human disease (Santos & Hoshino 
2005; Martella et al., 2010). Conventionally, rotavirus strains are denoted by the P serotype name 
first, followed by its genotype in brackets, followed by the G-type (Clark et al., 2008). Common 
serotypes of RV infected humans include P[8]G1, P[4]G2, P[8]G3 and P[8]G4 (Gentsch et al., 
1996).  
 
Transmission and Pathogeneses of Rotavirus 
Rotavirus is believed to be transmitted via the fecal oral route, close personal contact, and 
contact with contaminated environmental sources. However, the prevalence of RV in high-
income countries despite improved sanitation suggests that nonfecal routes play a role in 
transmission, such as respiratory droplets (de Wit et al., 2003; Santosham et al., 1983) 
Upon ingestion, the RV targets the epithelial lining of the intestine (Greenberg et al., 
2009). During viral replication, the segments of the viral genome are disassociated from viral 
proteins and one another; this allows reassortment of genotypes in cells infected with more than 
one strain of RV (Desselberger et al., 2009). Rotavirus disrupts the normal functioning of the 
gastrointestinal mucosa through a number of mechanisms (Greenberg et al., 2009); the most 
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potent is the viral enterotoxin non-structural protein 4 (NSP4), which alters the permeability of 
the gut mucosa by weakening the tight junctions between cells, disrupting the cytoskeleton of the 
infected cells, increasing the secretion of chlorine ions, and stimulating the gut motility through 
the enteric nervous system (Ramig, 2004), which causes in an uncontrolled outflux of water into 
the intestinal lumen, resulting in profuse diarrhea. 
 
Clinical Symptoms 
Rotavirus disease is most commonly characterized by acute gastroenteritis. After an 
incubation period of 1-3 days (Bernstein, 2009), RV infections present with symptoms common 
to many enteric pathogens: profuse watery diarrhea, vomiting, and fever (Staat et al., 2002). The 
severity of symptoms varies, but on average is more severe than other viral enteric pathogens 
(Intusoma et al., 2008). It accounts for 25%–40% of diarrheal cases requiring hospitalization 
(Podewils et al., 2004). Diarrhea typically lasts from 4 to 7 days (Desselberger et al., 2009). 
Virus-specific diagnostic tests and treatment are not necessary as symptoms typically resolve 
within a week of disease onset (Cheng et al., 2005). However, supportive care, primarily rapid 
rehydration, is critical to preventing complications. The most common complication associated 
with RV infection is dehydration. Severe dehydration is characterized by reduced or altered 
consciousness, lack of urine output, low blood pressure, weak quickened pulse, cool moist 
extremities, and peripheral cyanosis (Duggan et al., 1992). Malnutrition and diarrhea form a 
destructive cycle in children and as the most common diarrheal pathogen in infants, RV plays an 
important role in this cycle. Nutritional support is a critical component of ameliorating the short-
term and long-term consequences of RV, as well as other diarrhea diseases. 
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Treatment of Rotavirus Infection 
Dehydration is responsible for 90% of deaths from infectious diarrhea (Claeson et al., 
1990). Treatment for RV gastroenteritis, as with the majority of infectious watery diarrhea, is 
supportive; children should receive appropriate hydration and nutritional support. The current 
World Health Organization (WHO) recommendation is for low-osmolarity oral rehydration 
solution (ORS, 245 mOsm/L) with 75 mmol/L each of sodium and glucose. In cases of severe 
dehydration in which the child is unable to drink, intravenous fluids should be used for initial 
management, with the institution of ORS as soon as possible. The WHO also incorporated early 
refeeding into their recommendations for diarrhea treatment (Chandran et al, 2010).  
Antimicrobial therapy should be used only in specific cases of infectious diarrhea and in 
general do not have a role in the treatment of RV gastroenteritis. Probiotics, microorganisms 
believed to restore microbial balance in the gastrointestinal tract, may have a role in the 
treatment of diarrhea by enhancing the immune response or providing a competitive blockage of 
pathogen receptor sites. In a meta-analysis of seven clinical trials, Lactobacillus GG (LGG) was 
shown to reduce the duration of rotavirus diarrhea by 2.1 days (95% CI: 3.6-0.6) (Szajewska et 
al., 2007); however, a recent trial in rural India did not show any efficacy (Misra et al., 2009). 
Saccharomyces boulardii and Lactobacillus reuteri have also shown beneficial effects for RV 
gastroenteritis (Guandalini, 2008). Additional studies are needed to further define the necessary 
dose and duration of treatment, particularly in developing country settings. Although the 
morbidity and mortality from rotavirus gastroenteritis differ across socioeconomic strata, rates of 
illness are similar across developed and developing country settings. This indicates that hygiene 
and sanitation improvements, which have been credited with reducing incidence of most causes 
of infectious diarrhea in developed countries, are unlikely to prevent RV disease significantly 
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(Dennehy, 2008). Therefore, prevention in the form of vaccines is essential for the control of RV 
disease. 
 
Rotavirus Vaccine 
Children vaccinated with oral live vaccines develop a humoral immune response and are 
protected against severe disease upon reinfection. Protection against rotavirus infection has been 
associated with the presence of antirotavirus IgA antibodies in the gastrointestinal mucosal 
surface (Fischer et al, 2002). Although levels of serum anti-RV IgA do not always correlate with 
levels of IgA antibody in the gut, the IgA response is often used to measure vaccine immune 
response. A few studies have demonstrated that both presence of serum IgA and presence of 
serum IgG are protective. O’Ryan et al. (1994) reported that children who were infected during 
the second season of the study had significantly lower geometric mean titers of RV IgA and IgG 
than did those who were not subsequently infected.  
Considerable efforts have been made over the last 30 years to develop safe and effective 
rotavirus vaccines for human infants (El-Attar et al., 2009). In December 2009, WHO 
recommended routine immunization of infants for prevention of RV disease. Currently, two RV 
vaccines, Rotarix® (GlaxoSmithKline, Research Triangle Park, NC) and Rotateq® (Merck & Co 
Inc, Whitehouse Station, NJ), based on an attenuated G1P [8] human rotavirus or a mixture of 
five human-bovine reassortant rotaviruses of different G-types, have been developed and  
licensed for use in both developing and developed countries. 
Rotarix is a monovalent vaccine composed of an attenuated human rotavirus strain 
G1P[8]. Three clinical trials involving 5,024 infants conducted in Finland, Latin America and 
Singpore indicated a good immunogenicity of this vaccine (De Vos et al., 2004). Many reports 
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indicate that serum IgA antibodies are important for immunity to rotavirus and resistance to 
symptomatic re-infection (Yuan et al., 1996; Johansen & Svensson, 1997). In the 3 trials, 61–91% 
of vaccinated infants developed RV-specific serum IgA antibodies after 2 doses, depending on 
Rotarix® potency (De Vos et al., 2004). Rotarix significantly decreased RV gastroenteritis 
episodes (over 85%~96% protection against moderate to severe gastroenteritis) and related 
hospitalizations in vaccinated infants, as compared to placebo (De Vos et al., 2004).  In a recent 
trial conducted in healthy Indian infants, Rotarix increased RV-specific IgA concentrations more 
than two-fold in 60.5% of infants, while 7.5% of placebo recipients showed a two-fold increase 
(Narang et al., 2009). Thus, this vaccine proved to be nonreactogenic, well tolerated and not 
associated with intussusception. This oral rotavirus vaccine is administered in two doses at 
approximately 6-24 weeks of age (O'Ryan, 2007). The first dose may be administered from the 
age of 6 weeks and there should be an interval of at least 4 weeks between doses (O'Ryan, 2007).  
The vaccination course should preferably be given before 16 weeks of age and must be 
completed by the age of 24 weeks (O'Ryan, 2007).  
 
1.3 Gastrointestinal Development and Piglet Model 
 
General Overview 
The small intestine is the largest component of the digestive tract and the major site of 
digestion and absorption. It is divided into three parts, the duodenum, the jejunum and the ileum.  
The epithelium of the small intestine consists of the following cell types: 
Enterocytes or absorptive cells. The predominant cell type of the epithelium is the 
enterocyte or absorptive cell. They are tall columnar cells with microvilli and a basal nucleus, 
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specialized for the transport of substances. Amino acids and monosaccharides are absorbed by 
active transport, monoglycerides and fatty acids cross the microvilli membranes passively. 
Absorbed substances enter either the fenestrated capillaries in the lamina propria just below the 
epithelium, or the lymphatic lacteal (most lipids and lipoprotein particles). Enterocytes have a 
lifespan of about 5-6 days.  
Goblet cells. These mucus-secreting cells are the second most abundant epithelial cell. 
They are found interspersed among the other cell types. Their mucous is a very large 
glycoprotein that accumulates at the apical end of the cell, rendering it wide. The slender base of 
the cell holds the nucleus and organelles. Goblet cells usually appear pale or empty due to the 
loss of their contents upon preparation. Their lifespan is also 5-6 days.  
Paneth cells. Paneth cells are found only in the bases of the crypts. These cells have an 
oval basal nucleus and large, refractile acidophilic granules at their apical end. Paneth cells also 
phagocytize some bacteria and protozoa. They may have a role in regulating intestinal flora. 
They have a lifespan of about four weeks.  
Enteroendocrine cells. They are most often found in the lower part of the crypts but can 
occur at all levels of the epithelium. Their most abundant products here are cholecystokinin or 
CCK, which stimulates pancreatic enzyme secretion. 
M or microfold cells. These cells are epithelial cells that overlie Peyer’s patches and 
other large lymphatic aggregations. They are relatively flat and their surface is thrown into folds, 
rather than microvilli. They endocytose antigens and transport them to the underlying lymphoid 
cells where immune responses to foreign antigens can be initiated. 
Undifferentiated cells. These stem cells are found only at the base of the crypts and give 
rise to all the other cell types. A cell destined to be a goblet cell or enterocyte undergoes about 2 
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additional divisions after leaving the pool of stem cells, and migrates from the crypt to the villus. 
It will be shed at the tip of the villus. 
 
Cell Proliferation 
Crypt cell proliferation is markedly increased in sow reared piglets in the first two days 
of life followed by decrease at day 7 and week 12 (Zabielski et al., 2008).  The proliferative 
crypt cells are higher in DNA content while the villus epithelial cells have more protein (Fan et 
al., 2001). The typical life span of enterocytes in the proximal small intestine is twice as long as 
the distal in 14-to 18-day old piglets fed sow milk replacer formula (Fan et al., 2001). At birth, 
the gastrointestinal tract is immature in the piglet, but villus height is considerable in length 
(Thymann et al., 2006).  Small intestinal morphology has previously been used as a marker of 
intestinal health in piglets by extensive studies (Chen et al., 2005; Houle et al., 1997; Oliver et al., 
2002). 
  
Digestive Enzyme Activity 
Sucrase-isomaltase (EC 3.2.1.10) and lactase-phlorizin hydrolase (EC 3.2.1.23-62) are 
digestive enzymes located on the brush border membrane facing the small intestinal lumen and 
are used as a marker of digestive capacity in the small intestine, as well as serving as indicators 
of  enterocyte maturity (Adeola & King, 2006).  
Lactase-phlorizin hydrolase (LPH) is the major intestinal disaccharidase responsible for 
the hydrolysis of the lactose in milk and is, thus, an important factor in energy utilization in 
developing mammals. The expression of LPH activity is developmentally programmed and 
reaches a maximum late in gestation, presumably to prepare the newborn for digestion of milk 
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lactose (Sangild et al., 2000; Buller et al., 1990). In the neonatal intestine, several factors have 
been shown to affect the expression and activity of LPH, including diet (Oliver et al., 2002), the 
proximal-distal location (Houle et al., 1997) and stage of enterocyte differentiation along the 
crypt-villus axis (Rings et al., 1992). At the cellular level, the production of LPH is subject to 
multiple sites of regulation at the transcriptional, translational and posttranslational levels (Burrin 
et al., 2001). In pigs, at least two isoforms of prolactase-phlorizin hydrolase (pro-LPH), one 
mannosylated and the other bearing complex glycosidic side chains, have been isolated from the 
small intestinal mucosa. Furthermore, the complex glycosylated precursor form is cleaved 
proteolytically before insertion into the brush-border (BB) membrane as BB-LPH (Burrin et al., 
2001).   
Lactase and sucrase have been reported to increase significantly before birth in the last 
20 % gestation (Sangild et al., 2002). Lactase activity in a newborn piglet is high at birth 
followed by a decline within the first 2 months of age (James et al., 1987). This decline may be 
delayed if the post weaning diet contains high amounts of lactose (Marion et al., 2005).  Sucrase, 
which is a part of the sucrase-isomaltase complex, is nearly absent at birth until approximately 4-
6  days of age, followed by increases in activity with age (Adeola & King, 2006; James et al., 
1987) 
In summary, morphology and digestive enzyme activity serve as good markers of 
structural and functional capacity in the small intestine. At birth, the GI is relatively immature, 
but immediate introduction of nutrients promotes villus growth, protein synthesis, cell 
proliferation, as well as maturation and development in the activity and expression of brush 
border enzymes. As cells proliferate and migrate along the crypt-villus axis, they differentiate to 
mature enterocytes with increased expression of enzymes.  Diet is associated with the regulation 
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of these digestive enzymes through transcription, translation, and posttranslational events, 
suggesting the potential role in modulating brush border enzyme activities.  
 
Piglet as a Model for the Infant Intestinal Development 
The piglet model is a long established model used for both enteral and parenteral 
nutritional studies of human neonates  (Moughan et al., 1992; Wykes et al., 1993). Compared 
with rodents, the neonatal pig has more anatomical, physiological, immunological, and metabolic 
similarities with the human infants (Moughan, et al., 1992). 
In the piglet model, the small intestinal weight increases by 70-80 % in the last 3-4 weeks 
of gestation, coinciding with increase of tissue specific activities of brush border enzymes 
(Bjornvad et al., 2005). The small intestine undergoes tremendous growth and functional 
changes in the immediate pre- and postnatal periods and these changes may be diet-dependent 
(Bjornvad et al., 2005). In preterm piglets, formula-feeding is associated with decreased 
intestinal growth and brush-border enzyme activities, compared to colostrum-feeding (Bjornvad 
et al., 2005).   
 
Piglet as a Model for RV vaccination 
Due to the impervious nature of the sow placenta to immunoglobulins pigs are born 
devoid of maternal antibodies (MatAb), acquiring serum Igs by intestinal absorption of 
colostrum Igs for up to 36 h after birth before gut closure (cessation of absorption of intact Ig) 
occurs (Banks & McGuire, 1989), facilitating experimental manipulation of levels of maternal 
antibodies. 
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Interference of Neonatal Active Immune Responses by MatAb 
Vaccination of neonates faces many challenges due to the immaturity of the neonatal 
immune system and interference by maternal antibodies (MatAb) present at vaccination. 
Interference of vaccine-induced immune responses by MatAb has been reported for both live 
vaccines and non-replicating vaccines.  The degree of interference may depend on the ratio 
between the amount of MatAb and the antigen present (Arias et al., 2001). Optimal amounts of 
MatAb can enhance B-cell responses by forming antigen-antibody complexes that induce 
complement deposition. On the other hand, neutralizing MatAb neutralize live vaccines and 
reduce the antigen mass available for immune response induction. Thus, the outcomes of MatAb 
effects, whether positive (enhancing) or negative (suppressing) are dependent on the MatAb 
titers, the vaccine, and the dose and type of antigen (Arakawa et al., 1998). Rotavirus infections 
occur as early as under 3-months of age in infants even when the levels of MatAb in the 
circulation (acquired from placental transfer) and intestine (acquired from breast milk) remain 
high.  
The variable efficacies and seroconversion rates in many rotavirus vaccine trials in 
human infants were influenced by the effects of MatAb on vaccine take and immunogenicity 
(Andrew et al., 1992). Various titers of RV specific MatAb at vaccination have been shown to 
influence the outcome of active immunity.  Nguyen et al. (2006) reported that high titers of 
circulating maternal antibodies suppressed effector and memory B-cell responses induced by an 
attenuated (Att) human RV (HRV) priming and RV-like particle-immunostimulating complex 
(VLP-ISCOM) boosting vaccine regimen. Virus-like particles (VLP) offer attractive approaches 
for neonatal RV vaccines due to their potential safety (non-replicating so lack of infectivity) 
compared to live vaccines. However, low titer  maternal antibodies (LoMatAb) had both 
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enhancing and suppressing effects on B cell responses to a combined live attenuated HRV and 
VLP-ISCOM vaccine, depending on tissue, antibody isotype and vaccine (Nguyen et al. 2006). 
In Nguyen’s study on the AttHRV/VLP (replicating) vaccine, LoMatAb enhanced intestinal IgM 
and IgA antibody secreting cell (ASC) numbers at various times (pre- and post- challenge). 
However, there was evidence for suppression of systemic antibody responses by LoMatAb, 
especially systemic IgA ASC, IgA memory B cells in peripheral blood and serum IgA antibody 
responses. Therefore, the AttHRV/VLP vaccine partially overcame LoMatAb suppression, 
conferred moderate protection against virulent HRV and represents a new candidate for rotavirus 
vaccines for both humans and animals (Nguyen et al. 2006).  
 
Piglet Models for RV Infection and Vaccination 
Pigs are the only animals in which diarrhea can be induced by HRV strains, which make 
them more relevant for the study of RV vaccines for use in human infants. The window of 
susceptibility of pigs is longer (up to 8 weeks or more after birth), which allows studies of the 
immune responses and the evaluation of vaccine efficacy with booster doses (Richards et al., 
1998; Ward et al., 1992) . Conventional pigs (raised under normal conditions) have been used by 
many investigators, but pigs varied in age, the presence or absence of MatAb (colostrum fed or 
deprived pigs) and the confounding effects of extraneous RV infectious. Therefore, there are 
currently two pig models for the study of RV induced protection and immune responses: the 
gnotobiotic pigs (raised in germ-free conditions) and colostsrum-deprived, cesarean-derived pigs.  
Gnotobiotic Piglet Model.  Neonatal Gnotobiotic (Gn) pigs have been used extensively to 
study immune responses to RV, RV vaccines and the correlates of protective immunity. Studies 
were conducted of the magnitude and kinetics of IgM, IgA and IgG ASC in pigs inoculated with 
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porcine RV SB1A and Gottfrield strains or HRV Wa strain using an ELISPOT assay (Chen et al., 
1995). The IgM ASC appears as early as 3 days after infection and peak at 7 days post-
inoculation (PID) in MLN and spleen and later in lamina propria (LP) of the intestine. The IgA 
and IgG ASC numbers peak later at PID 14-21 and the IgA ASC responses are found mostly in 
intestinal lymphoid tissues. The magnitude of the antibody responses is highest in the tissues 
close to the site of viral replication, i.e. the intestine. In the Gn pig model, a correlation of 
protection against infection and disease has been associated with intestinal IgA ASC, whereas 
the IgA ASC and antibodies in blood can serve as indicator of the IgA intestinal response, and 
hence protection (Yuan et al., 1996). The route of vaccine delivery has also been investigated 
intensively in the Gn model. The administration via mucosal routes has shown clear advantages 
over the systemic route in inducing mucosal antibody responses as well as in the ease of delivery 
of the vaccine. The order of the routes used for priming and boosting also determines the level of 
protection in pigs. Oral priming and intranasal boosting strategies used in rotavirus vaccine 
studies of gnotobiotic piglets were highly effective in inducing antibody responses, presumably 
due to exploiting multiple mucosal inductive sites. This strategy of avoiding mucosal sites where 
booster vaccines may be neutralized by local antibodies induced by the priming vaccine assures 
that booster vaccination will evoke effective antigenic stimulation (Yuan et al., 2001). Although 
used as a well-established model, Gn pigs require expensive surgical procedures and the specific 
pathogen-free facilities are not always available.  
Colostrum-Deprived, Cesarean-Deprived Piglet Model.  An alternative to Gn pig model 
is the use of colostrum-deprived, artificially-reared piglets, which possess similar susceptibility 
to RV infection, clinical signs and intestinal pathology as human infants or Gn pigs (Gomez, 
1997; Zijlstra, 1999). An advantage of this model over the Gn piglet is bacterial colonization of 
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the intestinal tract, which is critical to the intestinal barrier development and protection of the 
host against pathogens (Chen & Walker, 2005). Moreover, in order to investigate potential 
nutritional interventions, the presence of the intestinal microbiota, human infants would exhibit, 
is critical. One of the limitations of this model is its susceptibility to infection by a wide variety 
of pathogens including RV. Bovine colostrum has a critical role in postnatal health as an immune 
booster. Bovine colostrum is an extremely important source of immunoglobulins; the 
concentrations of IgG, IgM, and IgA are 100-fold higher than in normal milk (Rooke and Bland, 
2002). Bovine colostrum supplementation has been shown to increase total serum IgA 
concentrations in weaned piglets (Boudry et al., 2007). Therefore, bovine colostrum was used in 
our first oral OPN supplementation study.  
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Figure 1.1 OPN structure (Wang &  Denhardt, 2008). From left to right are 
indicated: the N-terminal signal sequence regulating OPN secretion that is 
cleaved off when the protein is secreted; a region rich in aspartate residues 
responsible for strong binding to hydroxyapatite; the sites of O-glycosylation N-
terminal to the GRGD sequence responsible for integrin interactions; the site of 
cleavage by thrombin immediately C-terminal to the YGL sequence; the likely 
region of interaction with CD44 variants towards the C-terminal portion of the 
protein. Sites susceptible to cleavage by matrix metalloproteinases are also 
noted; grey dots indicate potential regions of serine/threonine phosphorylation 
scattered throughout the protein. 
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Figure 1.2 Comparison of osteopontin protein sequences. The amino acid sequences from six mammalian (rat, mouse, cow, 
pig, human, and rabbit) and one avian (chicken) species have been aligned by means of the multiple alignment program of 
Thompson et al. (1994) to maximize identical (dark shading) and similar (light shading) amino acids identified by JavaShade 
(Southern and Lewis, 1998; http://industry.ebi.ac.uk/JavaShade/) to reveal conserved structures. The 16-amino-acid leader 
sequence beginning with a methionine (position 1) is included with the first amino acid of the processed protein starting at 
position 17.  
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 Figure 1.3 OPN interacts with different signaling pathways to mediate 
immune responses (Wang &  Denhardt, 2008). (1) Engagement of extracellular 
OPN (sOPN in blue) to integrin avβ3 signals through the Src and FAK tyrosine 
kinases to activate transcription factor NFκB. OPN promotes phosphorylation of 
IκBα, which leads to the degradation of IκBα and nuclear translocation of NFκB 
which regulates the transcription of a variety of pro-inflammatory cytokines and 
mediators (Vejda et al., 2005). (2) In plasmacytoid DCs, intracellular OPN (iOPN 
in red) is associated with MyD88 during TLR9 engagement with viral DNA in the 
endosome, promoting TLR9 signaling toward IRF7 rather than IRF-5/NFκB, 
which would allow for robust IFN-γ production (Shinohara et al., 2006). (3) OPN 
interaction with CD44 activates PI3k/Akt signaling, which can mediate cell 
survival (Packer et al., 2006). 
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 Figure 1.4 OPN’s role in the regulation of innate and adaptive immunity 
(Wang &  Denhardt, 2008). (1) Exogenous pathogens activate TLRs on the 
surface of cells, including macrophages, neutrophils and immature dendritic 
cells. OPN is secreted by macrophages and dendritic cells when challenged by 
foreign antigens and enhances the activation and functions of these cells. OPN 
promotes neutrophil migration towards the site of injury. (2) OPN promotes 
immature dendritic cells to mature and migrate to draining lymph nodes, where 
they present processed antigens through the MHC to naive T cells and initiate a 
cell-mediated immune response. (3) Signals from DCs activate naive T cells 
and determine the polarization of T cells to Th1 or Th2 type cytokine 
responses. (4) Macrophages produce large amounts of OPN, which in an 
autocrine/paracrine manner contributes to the migration of macrophages and 
the expression of the pro-inflammatory cytokine IL-12. (5) OPN produced by 
various immune cells at inflammatory sites promotes infiltration of neutrophils. 
(6) Activated T cells are promoted by IL-12 to differentiate towards the Th1 
type, producing Th1 cytokines (IL-12, IFN-γ). OPN inhibits production of the 
Th2 cytokine IL-10, which leads to an enhanced Th1 response. (7) OPN 
promotes B lymphocyte proliferation and immunoglobulin production. 
36 
 
 
Figure 1.5 Possible effects of OPN on the innate and adaptive immune responses in mucosal tissues (Sodek et al., 2006).  
A. OPN expressed by epithelial and immune cells acts as a chemoattractant to macrophages and neutrophils and regulates their 
phagocytic activity, reactive oxidative burst (ROS) and release of cytokines, and proteolytic enzymes.  
B.  OPN can modulate the inflammatory reaction and promote repair through its effects on T-cell differentiation and by its ability 
to influence the survival of epithelial cells, macrophages, and fibroblasts. 
 
A B 
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Figure 1.6 Rotavirus structures. Rotavirus particles are icosahedrons, 70–75 
nm in diameter, composed of three concentric layers of structural proteins: the 
core, an inner capsid, and an outer capsid.  The outer capsid is composed of a 
viral protein 7 (VP7) coating with VP4 spikes protruding from the viral 
surface (Greenberg et al., 2009). This layer is the most antigenically important 
portion of the virus, with the VP7 glycoprotein (G-type antigen) and VP4 
protease-sensitive protein (P-type antigen) being the major immunological 
targets of the human immune system (Greenberg et al., 2009). The inner 
capsid is composed solely of VP6. Based on the antigenic properties of VP6, 
rotaviruses are broken into 7 serogroups, denoted A–G (Jayaram et al., 2004). 
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Chapter 2 
Effect of Osteopontin on Intestinal Development of Neonatal Piglets 
 
Abstract 
The objectives of this study were to investigate the effects of osteopontin (OPN) on piglet 
intestinal development. Newborn, colostrum-deprived piglets (n=27) were randomized to receive 
three treatments: formula with bovine OPN (OPN; 140 mg/L); formula alone (FF); or sow 
reared (SR) for 21 days. Body weight, intestinal weight and length, mucosal protein and DNA 
content, disaccharidase activity, villus morphology, and crypt cell proliferation were measured. 
Statistical significance was assigned at P<0.05. No significant effects of OPN were observed for 
body weight, intestinal weight and length. Mucosal protein content of SR piglets was lower than 
FF and OPN piglets in the duodenum, but higher than FF and OPN piglets in the ileum. No 
significant effects of diet in mucosal DNA content were detected for the three regions of the 
small intestine. Lactase and sucrase activities of SR piglets were higher than the two formula-fed 
groups in the duodenum, lower in the ileum. No significant differences in lactase and sucrase 
activities were noted between FF and OPN piglets in the duodenum and ileum. FF piglets had 
higher jejunal lactase activity than SR piglets, whereas no significant effect of diet was observed 
in jejunal sucrase activity among the three groups. Duodenal and ileal villus length and villus 
area of SR piglets were lower than two formula-fed groups, while OPN piglets did not differ 
from FF piglets. There was a significant effect of diet (P<0.0001) on jejunal crypt cell 
proliferation, with proliferation in OPN piglets being intermediate between FF and SR.  In 
summary, supplemental OPN increased jejunal crypt cell proliferation, independent of evident 
39 
 
morphological growth, and had a minor impact on lactase activity in the small intestine of 
neonatal piglets.  
 
Introduction 
 
Human milk is an excellent source of nutrition for infants and it contains a wide variety 
of bioactive proteins that are known to stimulate cellular growth and differentiation in vivo and 
in vitro (Grosvenor et al., 1993; Donovan et al., 1994). However, a significant difference in 
protein composition exists between human milk, bovine milk and infant formulas  (Hambreus et 
al., 1977).  Human breast milk is the optimal form of nutrition for human infants (AAP, 1995); 
hence, efforts have been made to improve the composition of infant formulas to more closely 
mimic that of breast milk. Purifying proteins from bovine milk and supplementing these to infant 
formula has been done, for instance, adding α-lactalbumin (Trabulsi et al., 2011).  However, a 
less well-characterized bioactive protein in milk that could potentially play a role in 
gastrointestinal growth and development in infants is osteopontin (OPN). 
Osteopontin is a multifunctional protein that is implicated in a wide number of biological 
processes including cell survival, bone remodeling, and immune modulatory functions (Sodek et 
al., 2000). The protein is widely expressed in variety of tissues and is present in body fluids 
including blood, bile and milk (Sodek et al., 2000). It is expressed by a single gene in a cluster of 
SIBLING family proteins that share structural and functional properties (Fisher and Fedarko, 
2003) on the long arm of chromosome 4 in humans and chromosome 5 in mice. Osteopontin is 
synthesized as a ~ 34-kDa protein that is extensively modified by phosphorylation, glycosylation 
and sulfation prior to its secretion as a protein that can range in size from 44- to 75-kDa (Sodek 
40 
 
et al., 2000). The heterogeneity of the secreted protein reflects differences in these post-
translational modifications, which have been related to different functional activities associated 
with mineralization (Sodek et al., 2000) and cell attachment and signaling (Ashkar et al., 2000). 
However, most of the known functional activities of OPN can be attributed to highly conserved 
structural motifs (RGD sequence) involved in cell-surface CD44 and integrin receptors. 
Interactions between the centrally located RGD sequence (arginine-glycine-aspartate) and the 
αvβ3 integrin, which is highly expressed in macrophages and osteoclasts, have been well-
documented (Sodek et al., 2006).  Binding through integrin receptors, OPN modulates a variety 
of cellular activities, including cell migration and proliferation, survival, motility and 
phagocytosis, all of which involve the cytoskeleton and have an impact on the inflammatory 
responses of macrophages and the fibrotic activities of fibroblasts (Sodek et al., 2006).  Schack et 
al. (2009) demonstrated that the OPN concentration in human milk is in a range of 138 ± 79 
mg/L, which is considerably higher than OPN concentration in bovine milk and infant formulas 
Although OPN is present at a relatively high concentration in human milk, little research has 
been conducted to assess its potential role in gastrointestinal growth and development of infants. 
Previous studies from our laboratory demonstrated that the addition of OPN to infant formula 
modulated intestinal gene expression in neonatal Rhesus monkeys (Donovan et al., 2011). There 
was a remarkable difference in jejunal gene expression between monkeys fed standard formula 
vs. mother’s milk (1025 genes), whereas OPN supplementation reduced the difference in gene 
expression relative to BF by over 5-fold from 1025 to 225 genes. However, the intestinal tissue 
samples were not collected in this study and, thus, the changes in intestinal structure and function 
were unknown.  
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Our objective was to determine whether supplemental OPN have an impact on 
gastrointestinal structure and functional development in the piglet, a commonly used preclinical 
model for infant nutrition (Ebert et al., 2005). The human infant and neonatal piglet are similar in 
anatomy, physiology and disaccharidase levels (Chen et al., 2005; Walsh et al., 2009).  We 
hypothesized that supplementation of OPN to formula will influence intestinal development of 
piglets to be more similar to sow-reared piglets, compared to piglets fed with formula alone.  
 
Materials and Methods 
 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise 
indicated.  
 
Study Design and Dietary Treatments 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
at the University of Illinois. Newborn, colostrum-deprived piglets (n=27) were obtained by 
Cesarean section of term gestation sows (n=3), weighed, and littermates were randomized into 
one of three dietary groups: formula alone (FF, n=9), formula with osteopontin (OPN, n=8), or 
sow-reared (SR, n=10). Formula-fed piglets were administered bovine colostrum (Colostrum 
Plus, Jorgensen Laboratories, Inc., Loveland, CO)  in five feedings of 30 ml/feeding for the first 
24 hrs.  Powdered bovine colostrum was rehydrated at 350g/1.4L formula. Piglets were then fed 
a nutritionally-complete commercial piglet formula (Advance Liquiwean, MSC, Dundee, IL) 
comprised of 25% protein, 13% fat, 44% lactose, 6.5% ash, and containing levels of vitamins, 
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minerals, and trace elements to meet NRC requirements for piglets’ growth (NRC, 1998). On d2 
postpartum, piglets were administered 1ml of iron dextran (Durvet, Inc Blue Springs, MO) by 
intramuscular injection. Diets will be prepared as 20% solids with the addition of double distilled 
water in a blender (200g/Liter). Therefore, protein, fat and lactose were about 5%, 2.6% and 8.8% 
in the final formula, respectively. The bovine OPN was provided as a dried, purified powder by 
Arla Foods Ingr. (Vibjy P/S, Denmark).  The powder is ~ 83% purified OPN by weight.  It was 
diluted in double distilled water and was added to the formula immediately before feeding at a 
final concentration of 116 mg/L. Formula was offered at 360ml/kg/day divided into 14 equal 
feedings. Formula intake, stool consistency and activity scores were assessed daily (Correa-
Matos et al., 2003). Formula not consumed by the piglet was recorded at each feeding in order to 
accurately determine the volume of formula and OPN consumed daily. 
 
Sample collection  
On d21 postpartum, piglets were injected intraperitoneally with 5-ethynyl-2’-
deoxyuridine (EdU; Invitrogen Molecular Probes, Eugene, OR) at a dose of 2.5 mg/kg body 
weight at 2 hrs prior to euthanasia to measure rates of enterocyte proliferation.  5-ethynyl-2´-
deoxyuridine is a nucleoside analog of thymidine and is incorporated into DNA during active 
DNA synthesis. Piglets were sedated with Telazol (Tiletamine HCl and Zolazepam HCl, 
3.5mg/kg BW each, Pfizer Animal Health, Fort Dodge, IA) and then euthanized by an 
intracardiac injection of sodium pentobarbital (Fatal Plus, Vortech Pharmaceuticals, Dearborn, 
MI; 72mg/kg body weight). Blood and tissue samples were collected for analysis. Blood was 
collected by cardiac puncture into heparin-laced vials and serum was separated by centrifugation. 
A laporotomy was performed and the small intestine was quickly excised from the pyloric 
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sphincter to the ileocecal valve and its length was measured. The intestine was cut into three 
segments at 10% and 85% of the total small intestine length to separate duodenum, jejunum and 
ileum, respectively, and the weight of each intestinal segment was recorded. Sections (1-2 cm) of 
each intestinal segment were fixed in Bouin’s solutions or snap frozen in liquid nitrogen. The 
remaining intestinal segments were opened longitudinally and mucosa were collected from 
duodenum, jejunum and ileum by gently scraping the luminal surface with a sterile microscope 
slide and snap frozen in liquid nitrogen.  
 
 Intestinal Histomorpholgy 
Bouin’s-fixed sections of duodenum, jejunum and ileum were embedded in paraffin, 
sliced to approximately 5 μm with a microtome, and mounted on glass microscope slides and 
stained with hematoxylin and eosin. Images were captured using a Nanozoomer Digital 
Pathology System (Hamamatsu Corporation, Bridgewater, NJ) at 10× fields. Villus length, villus 
surface area, and crypt depth were measured in 6-8 well-oriented villi and crypts using the 
software AxioVision Rel. 4.8 (Carle Zeiss International, Germany). Villus surface area was 
assessed by outlining the outer surface of the villi within the AxioVision program which then 
calculated the surface area of the villi (Figure 2.1). 
 
Jejunal Enterocyte Proliferation 
Enterocyte proliferation was measured using the Click-iT® EdU assay to detect EdU 
incorporated into proliferating crypt cells. Detection is based on a click reaction, a copper (Cu+1) 
catalyzed covalent reaction between an azide and an alkyne. In this application, the EdU contains 
the alkyne and the Alexa Fluor® dye contains the azide. The small size of the dye azide allows 
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for efficient detection of the incorporated EdU using mild conditions. Standard aldehyde-based 
fixation and detergent permeabilization are sufficient for the Click-iT® detection reagent to gain 
access to the DNA. This is in contrast to BrdU (bromodeoxyuridine) assays that require DNA 
denaturation (typically using HCl or heat or digestion with DNase) to expose the BrdU so that it 
may be detected with an anti-BrdU antibody (Figure 2.2).  
In our study, formalin-fixed, paraffin-embedded jejunal samples were sliced to 
approximately 5 µm with a microtome, mounted on slides, and incubated at room temperature in 
a humidified chamber with a series of washes with which decreased in the fresh histoclear 
(National Diagnostics, Atlanta, GA), ethanol, PBS, 0.1% Triton/PBS and 3% bovine serum 
albumin (BSA)/PBS solution in order to dewax the samples.  The ethanol percentage decreased 
with subsequent washes (100%, 70%, 50%, 25%),  To detect cells labeled by EdU, the slides 
were stained with Alexa Fluor® 555 azide using the Click-iT® EdU Alexa Fluor® 555 Imaging 
Kits (Invitrogen, Molecular Probes) according to manufacturer’s instructions. Total nuclei were 
counterstained with DAPI (4', 6-diamidino-2-phenylindole dihydrochloride; Invitrogen, 
Molecular Probes). Approximately 6-8 randomly chosen crypt images per animal was captured 
using Zeiss LSM 700 confocal microscope (Carl Zeiss International) at 20× fields. Images were 
qualified based on color density by using the software AxioVision Rel. 4.8 (Carle Zeiss 
International, Germany). Proliferation was expressed as the percentage of EdU-labeled area 
divided by totally labeled area per crypt. 
 
Disaccharidase Activity 
Mucosal homogenates were prepared with 0.2 g intestinal mucosa into 2 ml of 
homogenization buffer containing protease inhibitors (0.45 mol/L sodium chloride, 0.002 mol/L 
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iodoacetic acid and 0.001 mol/L phenylmethylsulfonylfluoride [Sigma Chemical Co., St. Louis, 
MO]). After preparing the appropriate dilution in homogenization buffer (range of 0 to 1:20), the 
mucosal homogenates were incubated in either lactose or sucrose buffer for 60 min at 37 °C. The 
hydrolysis of the disaccharide by the action of the disaccharidase in the tissue homogenate was 
stopped by the addition of 2.0% zinc sulfate and 1.8% barium hydroxide. Following 
centrifugation and transfer of supernatant to a 96-well microplate, the amount of glucose released 
was detected using a glucose oxidase reagent (Thermo Scientific, Middletown, VA) using a 
microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). Disaccharidase activity was 
expressed as the amount of glucose released per gram of protein per minute (Dudley et al., 1992).  
 
Mucosal Protein and DNA content 
Mucosal homogenates were prepared as described above. For protein content, 
homogenates were diluted either 1:5 or 1:10 in homogenization buffer and transferred to a 96-
well microplate. Bovine serum albumin (BSA, Sigma Chemical Co.) was used to establish the 
standard curve. Following the addition of Bradford dye reagent, protein concentration was 
measured using a spectrophotometer (Molecular Devices).  For DNA content, homogenates were 
diluted 1:5 in 1x Tris-EDTA buffer solution and transferred to 96-well microplate, where 
samples were incubated with PicoGreen dsDNA quantitation reagent solution (Invitrogen, 
Molecular Probes, Eugene, OR) and measured using a fluorometer (Molecular Devices). Calf 
thymus DNA (Sigma Chemical Co.) was used to generate the DNA standard curve. 
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Statistical Analyses 
All data are expressed as mean ± standard error of the mean.  A one-way ANOVA was 
performed using a General Linear Model (GLM) with a post hoc LSD test using Fisher’s Least 
Significant Difference test to evaluate the effects of diet (Formula, Formula with OPN or sow 
milk). Normality of data was tested under Proc Univariate, and homogeneity of variance under 
the GLM procedure. A Wilcoxon non-parametric test was used under the GLM procedure if 
normality and/or homogeneity of variance were violated; data were expressed as Chi square 
value. Analyses were performed using SAS Version 9.2 (SAS Institute, Cary, NC). Statistical 
significance was assigned at P < 0.05, with a trend reported as P<0.10.    
 
Results 
 
Formula Intake and Body Weight  
Formula intake between d2 and d21 pstpartum was not significantly different between FF 
and OPN groups (p=0.3678). The mean formula intake of FF group and OPN group was 1077 ± 
52 ml/day and 1154 ± 65 ml/day, respectively. Therefore, daily intake of OPN is 44.2 mg/kg BW. 
The mean birth weight was similar among the three groups (1.28 ± 0.27 kg, p=0.3809). During 
the first 7 days, body weight tended to differ (p=0.0504); during the 14~21 days, the difference 
between the groups became significant (p=0.0003). Overall, SR piglets gained more weight than 
FF (p<0.0001) and OPN (p=0.0003) piglets during the 21-day study. There was no effect of OPN 
(p=0.5689) on body weight gain (Table 2.1, Figure 2.3). 
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Intestinal Weight and Length  
Intestinal length was unaffected (p=0.8035) by different feeding methods. However, the 
intestinal weight (g) of SR piglets was lower than FF (p=0.0021) and OPN (p=0.0151) piglets. 
Similarly, when normalized by body weight, the intestinal weight (g/kg) and intestinal length 
(cm/kg) of SR piglets were lower than FF (p<0.0001, p=0.0002) and OPN (p<0.0001, p=0.0008) 
piglets. Intestinal weight normalized by intestinal length (g/cm) was also lower in SR than 
formula (p=0.0004) or OPN (p=0.0120) piglets. There was no effect of OPN (p=0.2466, 
p=0.7417, p=0.2194) on any of the above measurements (Table 2.1). 
 
Mucosal Protein and DNA Content 
Protein. Mucosal protein content of SR piglets was lower than FF (p=0.0033) and OPN 
(p=0.0021) piglets in the duodenum. In the jejunum, there was no significant effect of diet 
among the three groups. Mucosal protein content of SR piglets was higher than FF (p=0.0136) 
and OPN (p=0.0023) piglets in the ileum (Table 2.2).  
DNA. There was no effect of diet on mucosal DNA content in the duodenum (p=0.2932), 
jejunum (p=0.9749) and ileum (p=0.2777) among the three groups (Table 2.2).   
 
Intestinal Histomorphology  
In the duodenum, the villus length and villus area of SR piglets were lower than FF 
(p=0.0051, p=0.0008) and OPN (p=0.0084, p=0.0006) piglets. There was no effect of OPN 
(p=0.9254, p=0.8372) on any of the above measurements (Table 2.3). OPN piglets had deeper 
(p=0.0013) crypts than SR piglets and tended (p=0.0928) to have deeper crypts than FF piglets. 
In the jejunum, no significant difference was observed among the three groups in the villus 
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length, villus area, and crypt depth. In the ileum, the villus length and villus area of SR piglets 
were lower than FF (p<0.0001, p<0.0001) and OPN (p=0.0002, p<0.0001) piglets. Crypt depth 
did not differ among three groups in the ileum (p=0.4147). There was no effect of OPN 
(p=0.7480, p=0.3809, p=0.6624) on any morphological outcome in the ileum (Table 2.3, Figure 
2.4 A, B, C). 
 
Jejunal Enterocyte Proliferation 
There was a significant effect of diet (P<0.0001) on jejunal enterocyte proliferation. EdU-
labeled area (%) per crypt significantly differed among SR (53.5±2.0%), OPN (41.6 ±1.9%) and 
FF (28.6±1.7%) groups. Therefore, DNA synthesis was nearly 2-fold higher in SR piglets 
compared with that in FF piglets, whereas OPN supplementation reduced this difference by 40% 
from about 2 folds to 1.2 folds (Figure 2.5).  
 
Disaccharidase Activity 
Lactase Activity. Lactase activity reached the highest levels in the jejunum of each group 
(P<0.0001). Duodenal lactase activity (µmol glucose/min/g protein) of SR piglets was higher 
than  FF (p=0.0041) and OPN (p=0.0002) piglets. FF piglets had higher (P=0.0075) jejunal 
lactase activity than SR piglets did.  OPN piglets tended to have lower jejunal lactase activity 
than FF piglets (P=0.0597), but no difference was observed between OPN and SR groups 
(p=0.2610). In contrast, lactase activity of SR piglets was lower than  FF (p=0.0002) and OPN 
(p=0.0002) piglets in the ileum. No effect of OPN on lactase activity was observed in the 
duodenum (p=0.1918) or ileum (p=0.9574) (Table 2.4, Figure 2.6). 
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Sucrase Activity. Sucrase activity reached the highest levels in the jejunum of each group 
(P<0.0001). Duodenal sucrase activity (µmol glucose/min/g protein) of OPN piglets did not 
differ from FF (p=0.3751) or SR (p=0.0671) piglets.  However, SR piglets had higher sucrase 
activity than FF (p=0.0113) in the duodenum, but lower sucrase activity than FF (p=0.0255) and 
OPN (p=0.0018) piglets in the ileum. In the jejunum, no significant difference in sucrase activity 
was noted among three groups. In summary, no effect of OPN on sucrase activity was identified 
in the duodenum, jejunum and ileum (Table 2.4, Figure 2.6).  
 
Discussion 
 
 Osteopontin is a highly phosphorylated and glycosylated acidic protein that is present in 
bovine (Bayless et al., 1997; Sorensen et al., 1995) and human (Nagatomo et al., 2004; Sorensen 
et al., 2003) milks, but is present at a very low concentration in infant formulas.  Methods have 
been developed to isolate OPN from bovine milk (Bayless et al., 1997), which creates the 
opportunity to supplement it to human infant formula. Milk-borne OPN may be important in 
pediatric nutrition for a variety of reasons. It is a multifunctional protein that is involved in both 
physiologic and pathophysiologic events, including the regulation of cell migration and 
proliferation (Sodek et al., 2006), tissue repair and angiogenesis (Liaw et al., 1998), cellular 
chemotaxis (Giachelli et al., 1998) and activation in inflammatory conditions (Ashkar et al., 
2000; Hwang et al., 1994).  
Despite its presence at relatively high concentrations in human milk and wide-ranging 
biological activities, little attention is focused on its effects on developmental ontogeny of the 
digestive functions. Previous research on neonatal Rhesus monkeys demonstrated that the 
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supplementation of OPN with infant formula regulated jejunal gene expression (Donovan et al., 
2011). The neonatal piglet is similar to the human infant with regard to the intestinal structure 
and digestive enzyme development (Aumaitre et al, 1978; Moughan et al., 1972), making it an 
ideal model to study the potential role of milk-borne bioactive protein in the neonate. Therefore, 
the goal of this study was to perform preclinical trials on neonatal piglets in order to determine 
the impact of bovine OPN on the gastrointestinal structural growth and functional development.  
Based on the formula intake of the OPN piglets, they consumed 44.2 mg/kg BW/d.  Since 
the OPN concentration of the formula was in a range of OPN concentration in human milk, daily 
exposure to OPN in milk would be similar to human infants. Previous studies reported that the 
mean plasma concentration of 3-month-old breast-fed infants (352 ng/ml) was approximately 10-
fold higher than that of adult serum (35 ng/ml) (Schack et al., 2009), suggesting either enhanced 
endogenous production of OPN in the infant vs. adult or potentially absorption of milk-borne 
OPPN. Unfortunately, at the present time, there is no antibody that recognizes porcine OPN. 
Therefore, we are unable to measure the concentrations of OPN in either sow milk or piglet 
serum, thus, OPN intake of the SR piglets or whether serum OPN concentrations were higher in 
OPN compared to FF piglets could not be assessed. 
Our first aim was to investigate the effects of different dietary treatments on body and 
intestinal structural growth. In this study, SR piglets gained more weight than FF and OPN 
piglets. We do not feel that this was due to any detrimental effect of formula feeding or OPN on 
normal growth and development of piglets. Rather, it likely reflects the improved lactation 
efficiency of the newer breed of swine that were introduced recently at the University of Illinois 
Swine Research Center. In the past, formula-fed piglets consuming 360 ml/kg/d demonstrated 
growth rates that were similar to those of SR piglets in litters of 10 (Correa-Matos et al., 2003; 
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Houle et al., 1997).  However, recent studies in our laboratory with the new line of piglets have 
demonstrated superior growth to SR piglets in litters of 10, compared to FF littermates. 
Moreover, protein content (5%) in our sow milk replacer was much lower than that in sow 
colostrum, but was comparable to sow milk. Fat content (2.6%) was consistently lower than sow 
colostrum and milk (>5%; Klobasa et al., 1987). Therefore, it is very likely that the higher 
concentration of fat in sow colostrum and milk developed more body weight in the form of 
subcutaneous and/or visceral fat in neonatal piglets, which was obviously observed during 
sample collection. Despite greater overall body weight gain, intestinal weight, either in absolute 
terms (g) or normalized by body weight (g/kg), of SR piglets compared with FF and OPN piglets, 
which confirmed that the formula-feeding met the nutrient requirement for intestinal growth. 
Additionally, in the duodenum, two formula-fed groups had higher levels of mucosal protein 
content than SR group. The higher ratios of mucosal protein to DNA indicated that accumulation 
of protein exceeded the rate of DNA synthesis, resulting in the hypertrophy of the enterocytes 
that lined the intestine. The presence of bigger enterocytes would be consistent with higher villi, 
larger villus surface areas and deeper crypts observed in both formula-fed groups. However, the 
apparent trophic effect of formula was not seen in the jejunum and ileum. The SR piglets are 
included as a “gold standard” reference, however, the most appropriate comparison to determine 
an effect of added OPN is between the two formula-fed treatment groups.  
Measuring DNA synthesis is an accurate method to detect cell proliferation. To 
determine the effects of oral OPN supplementation on enterocyte proliferation, the incorporation 
of EdU to the DNA backbone of proliferative cells was examined. Both soluble OPN, which 
works as a cytokine, and immobilized OPN, which function as an extracellular matrix protein, 
protect against apoptosis and induce survival and proliferation in several cell types. Several in 
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vitro studies have reported that OPN exerts pro-survival and/or proliferative effects on adherent 
cell types such as smooth muscle cells (Weintraub et al., 2000) and epithelial cells (Elgavish et al, 
1998). Liu et al. (2009) reported that the overexpression of OPN in human embryo kidney-293 
cells significantly increased the level of cell proliferation in vitro. Furthermore, OPN’s anti-
apoptotic and proliferative effects are mostly associated with tumorigenesis. It has been 
previously indicated that epidermal growth factor (EGF)-dependent proliferation of prostate 
cancer cells was amplified by OPN (Angelucci et al., 2004). To our knowledge, this study is the 
first to demonstrate the proliferative effects of OPN on the small intestinal epithelial cells in vivo. 
The significant higher jejunal enterocyte proliferation was noted in SR (53.5%) and OPN (41.6%) 
piglets, compared with FF piglets (28.6%). Although higher levels of DNA synthesis observed in 
SR and OPN piglets, there were no effects of dietary treatments on villus height and villus area, 
suggesting that OPN was promoting intestinal growth at a cellular level. It was previously 
reported that crypt cell proliferation was markedly increased in SR piglets in the first two days of 
life with a higher ratio of mitotic activity / apoptosis. (Zabielski et al., 2008) In contrast, this 
ratio was decreased on day 7 and week 12 (Zabielski et al., 2008). Therefore, although higher 
rate of enterocyte proliferation was noted in the jejunum, it is possible that higher apoptosis rate 
also occurred in this section. This developmental pattern was also consistent with the study in 
which there were little further increases seen in the small intestine of rats after infusion of EGF 
for longer periods, although EGF significantly increased enterocyte proliferation and crypt and 
villus area after 24 hours of EGF infusion (Berlanga-Acosta, et al., 2001). There was a tendency 
(P=0.065) for OPN piglets to have deeper crypts than SR piglets did in the jejunum, which may 
support the effects of OPN on enhancing the proliferation of enterocytes residing in crypts.  
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Our second aim was to measure digestive enzyme activities to evaluate the effects of 
OPN on the functional capacity of the intestine. We observed that FF piglets had higher jejunal 
lactase activity than SR piglets. The jejunal lactase activity of OPN piglets tended to be lower 
than that of FF piglets, but no difference was seen between OPN and SR piglets. However, this 
effect was not seen in the jejunal sucrase activity of OPN piglets. The mechanism underlying the 
tendency of the decrease in jejunal lactase in response to OPN supplementation remains to be 
elucidated, but could involve direct modulation of lactase gene expression or the 
posttranslational processing of the enzyme (Burrin et al., 1994). In addition, the results from 
gene microarray analysis in Rhesus monkeys studies (Donovan et al. 2011) demonstrated that 
galactose metabolism was one of the main differences in signaling pathways between FF and 
OPN groups. An earlier study (Smith et al., 1990) reported that galactose inhibited lactase 
expression by mouse jejunal enterocytes. Therefore, it is possible that different galactose 
metabolism may play a role in the decrease of lactase activity seen in OPN piglets. Furthermore, 
higher concentration of lactose (8.8%) in our sow milk replacer formula vs. sow milk (3.1~5.8% 
during 0 h ~ 21d; Klobasa et al., 1987) may attribute to the increase in lactase activity seen in FF 
piglets (Marion et al., 2005). SR piglets had higher duodenal lactase and sucrase activities than 
FF and OPN piglets, suggesting that formula-feeding reduced the lactose digestive capacity, 
specifically in the proximal part of the small intestine (Thymann et al., 2006). In contrast, SR 
piglets had lower lactase and sucrase activities than the other two formula-fed groups in the 
ileum. One possible explanation is that the lactose absorption in the proximal region of the small 
intestine of SR piglets are more efficient compared with the counterpart in FF and OPN piglets.  
Less lactose reached the ileum and, thus, less lactase activity was developed in this region. 
However, considering less lactose hydrolysis in the proximal section, relatively higher 
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concentrations of lactose may be responsible for the increase in the ileal lactase activity of two 
formula-fed groups. Taken together, our data suggests that sow milk and piglet formula may 
have differentiated effects on the development of the disaccharidase activities in the three 
sections of small intestine in neonatal piglets. In addition to the impacts of dietary treatments 
across the groups, a typical developmental trend was also observed in our study. The jejunum is 
the most active region of the intestine for digestion and absorption of dietary components. Thus, 
it was shown in our study that both lactase and sucrase activities reached the highest levels in the 
jejunum, compared with their counterparts in the duodenum and ileum, regardless of treatment 
groups. The decrease in lactase activity in the distal region of the small intestine was in 
agreement with the previous findings (Manners et al., 1972; Houle et al., 1997; Oliver et al., 
2002). 
OPN has been recognized as an important luminal regulator (Brown et al., 1992), due to 
its expression by epithelial cells covering luminal cavities capable of active secretion and 
absorption of nutrients. Indeed, earlier studies showing that epithelial cells secrete OPN first 
indicated that OPN is involved in controlling epithelial barrier permeability and secretory 
functions (Butler, 1989). Recent studies suggested that the constitutive expression of OPN by 
epithelial cells is required for maintaining the epithelial barrier in the intestines (Gassler et al., 
2002). In current study, the effects of OPN on intestinal morphology and digestive enzyme 
activities were minimal. However, it is very possible that OPN may have effects in the intestine 
that were not assessed herein.  OPN exhibits pro-survival and anti-apoptotic properties, and thus 
aids cell survival, wound healing and matrix formation. In a previous study of preterm piglets, 
OPN supplementation in formula was associated with a modest deccrease in necrotising 
enterocolitis (NEC) without any significant effects on gut structural and functional indices 
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(Møller et al., 2011). In that study, daily intake of OPN in preterm piglets was 6-fold higher than 
that used in our study. Therefore, further studies are needed to determine the effects of bovine 
OPN at different concentrations on the small intestinal growth and functional development in 
disease or infection model of piglets. Furthermore, a RGD cell-binding domain in OPN suggests 
that this protein might play a role in cell adhesion (Oldberg et al., 1986), which is a critically 
important for maintaining barrier function in the intestine. Osteopontin expressed by breast 
epithelium and purified from human milk promoted attachment and spreading of a variety of cell 
types, including epithelial cells (Brown et al., 1992) and behaved in similar fashion as adhesive 
proteins. A likely hypothesis is that OPN binds luminal epithelial cell surface integrins via its 
RGD domain. In addition, the finding that OPN is widely distributed on surfaces of specific 
populations of epithelial cells in the gastrointestinal tract, bile ducts, pancreatic ducts, urinary 
tracts and breast suggests that this protein may have a protective role in interactions between 
these epithelial surfaces and the external environment. Thus, OPN present in breast milk may 
protect the gastrointestinal epithelium of the nursing baby and the breast epithelium of the 
mother.  
In bovine milk, OPN is present as an intact protein or in several proteolytically generated 
N- and C-terminal fragments (Sørensen & Petersen, 1993b). Furthermore, bovine milk OPN was 
partially resistant to proteolysis by neonatal gastric juice (Chatterton et al., 2004). It is not known 
if all forms of OPN bind equivalently well to their cell surface receptors. However, isolated 
forms of OPN have been shown to bind to monocytes through a novel integrin receptor in vitro, 
thus enhancing phagocytosis. Given that we observed some differences between OPN and FF 
piglets, we are hypothesized that ingested OPN is able to able to bind to epithelial cell surface 
integrins in the small intestine of piglets.  In addition, previous work from our laboratory has 
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shown that the supplementation of OPN to formula at human milk concentrations decreased the 
differences in jejunal gene expression between formula-fed and mother-fed Rhesus monkeys 
(Donovan et al., 2011). Differences in signaling pathways regulating stem cell proliferation 
(WNT), gastrointestinal patterning (HEDGEHOG) and cell fate between secretory and 
absorptive lineages (NOTCH) were differentially expressed among the groups. Future studies 
will assess gene expression in the jejunum of these piglets using gene microarray to determine 
whether supplemental OPN is also modulating the intestinal transcriptome of piglets.  
In summary, the addition of OPN in formula increased jejunal crypt cell proliferation, 
independent of evident morphological growth, and had a minor impact on lactase activity in the 
small intestine of neonatal piglets. Bovine OPN at human milk concentrations may not 
significantly affect intestinal structure and functional development in healthy, growing neonatal 
piglets. Therefore, further studies are needed to determine the functional fragments of bovine 
OPN and the effects of bovine OPN at different concentrations on the small intestinal growth and 
functional development in disease or infection model of piglets.  
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Figure 2.1 The measurements of intestinal histomorpholoy. Images were captured using a Nanozoomer Digital 
Pathology System (Hamamatsu Corporation, Bridgewater, NJ) at 10× fields. Villus length, villus surface area, and crypt 
depth were measured in 6-8 well-oriented villi and crypts using the software AxioVision Rel. 4.8 (Carle Zeiss International, 
Germany) (Figure 2.1).  Villus surface area was assessed by outlining the outer surface of the villi within the AxioVision 
program which then calculated the surface area of the villi. 
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         Figure 2.2 Detection of the incorporated EdU with the Alexa Fluor® azide versus incorporated BrdU with  
         an anti-BrdU antibody. The small size of the Alexa Fluor® azide eliminates the need to denature the DNA for the  
         EdU detection reagent to gain access to the nucleotide. 
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Figure 2.3 Formula intake and body weight gain. Overall, SR piglets gained more 
weight than FF (p<0.0001) and OPN piglets (p=0.0003) during the 21-day study (top 
panel). Formula intake between d2 and d21pstpartum was not significantly different  
between FF and OPN groups (P=0.3678) (bottom panel). There was no effect of OPN  
(p=0.5689) on body weight gain. Abbreviations: FF, formula-fed; OPN, formula with 
OPN; SR, sow-reared.  
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Intestinal Histomorphology
1,2, 3
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Figure 2.4A & B Intestinal histomorphology. 
1. FF, formula-fed; OPN, formula with OPN; SR, sow-reared  
2. DUOD, duodenum; JEJ, jejunum; ILE, ileum 
3. abc Values within intestinal sections (DUOD, JEJ or ILE) lacking a common 
letter differ at P<0.05. 
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Jejunal Enterocyte Proliferation 
C. Crypt 
Depth 
(µm) 
Figure 2.4C Intestinal histomorphology 
1.   FF, formula-fed; OPN, formula with OPN; SR, sow-reared  
2.   DUOD, duodenum; JEJ, jejunum; ILE, ileum 
3.      abc Values within intestinal sections (DUOD, JEJ or ILE) lacking a common   
      letter differ at P<0.05. 
Figure 2.5A Effects of diet on jejunal crypt cell proliferation. There was a significant 
effect of diet on jejunal crypt cell proliferation. EdU-labeled area (%) per crypt 
significantly differed among SR (53.5 ± 2.0%), OPN (41.6 ± 1.9%) and FF (28.6 ± 1.7%) 
groups.  Bars with different letters indicate significant differences between different dietary 
treatment groups at p < 0.0001. Abbreviations:  FF, formula-fed; OPN, formula with OPN; 
SR, sow-reared. 
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Jejunal Crypt Cell Proliferation (%) (21-day piglets) 
 Figure 2.5B Effects of diet on jejunal crypt cell proliferation. There was a significant effect (p<0.0001) of diet on 
jejunal crypt cell proliferation. Abbreviations:  FF, formula-fed; OPN, formula with OPN; SR, sow-reared. 
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Figure 2.6 Intestinal disaccharidase activity.  
abc Values within intestinal sections (DUOD, JEJ or ILE) among groups or  
*values between sections within group lacking a common letter differ at P<0.05. 
A. Intestinal Lactase Activity 
B. Intestinal Sucrase Activity 
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          Table 2.1 Body weight and intestinal weight and length.1,2,3 
FF OPN SR P value 
Body Weight Gain (kg) 4 4.33 ± 0.18b 4.50 ± 0.24b 5.75 ± 0.20a <0.0001
Intestinal Length (cm) 801.1 ± 24.63 821.3 ± 35.90 796.5 ± 22.40 0.8035 
Intestinal Weight (g) 279.9 ± 13.40a 268.5 ± 10.90a 237.3 ± 5.69b 0.0051 
Intestinal Weight/BW (g/kg) 49.6 ± 2.08a 46.2 ± 2.70a 31.61 ± 1.23b <0.0001
Intestinal Length/BW (g/kg) 142.6 ± 5.70a 140.1 ± 4.20a 111.6 ± 5.30b <0.0003
Intestinal Weight/Length (g/cm) 0.35 ± 0.01a 0.33 ± 0.01a 0.28 ± 0.01b 0.0012 
             1 Data are expressed as mean ± SEM 
             2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; SR, sow-reared  
             3 Means within a row without a common letter differ at p<0.05 
             4 Body weight change between d1 and d21 of age 
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     Table 2.2 Protein and DNA content.1,2,3 
  FF OPN SR p-value 
Protein (mg/g mucosa) 
DUOD 92.8 ± 3.11a 94.0 ± 1.93a 79.6 ± 3.26b 0.0026 
JEJ 83.5 ± 4.21 80.8 ± 2.70 77.6 ± 3.23 0.5061 
ILE 68.5 ± 3.54b 64.5 ± 4.16b 80.6 ± 1.79a 0.0056 
DNA (μg/g mucosa) 
DUOD 35.6 ± 3.42 28.8 ± 3.83 33.9 ± 1.73 0.2932 
JEJ 24.6 ± 3.42 23.9 ± 2.65 23.8 ± 2.35 0.9749 
ILE 36.7 ± 4.00 35.0 ± 2.64 42.6 ± 3.53 0.2777 
      1 Data are expressed as mean ± SEM 
      2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; SR, sow-reared; DUOD, duodenum; JEJ, jejunum; ILE, ileum 
      3 Means within a row without a common letter differ at p < 0.05 
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        Table 2.3 Intestinal Histomorphology.
1,2,3 
 
  FF OPN SR p-value 
Villus Height (µm) 
  DUOD 712.4± 9.89
a
 708.1 ± 39.35
a
 580.9 ± 25.24
b
 0.0067 
JEJ 682.0 ± 37.29 637.2 ± 18.85 661.0 ± 50.47 0.7564 
ILE 1014.4 ± 50.82
a
 1044.4 ± 75.15
a
 608.1 ± 61.34
b
 <0.0001 
 
Villus Area (µm
2
×1000) 
DUOD 76.55 ± 4.59
a
 77.96 ± 4.86
a
 59.78 ± 2.67
b
 0.0005 
JEJ 65.34 ± 4.73 66.12 ± 3.69 58.12 ± 5.69 0.4664 
ILE 117.2 ± 6.41
a
 126.9 ± 9.93
a
 55.79 ± 6.26
b
 <0.0001 
 
Crypt Depth (µm) 
DUOD 100.3 ± 3.41
a
 113.4 ± 4.80
a
 90.6 ± 7.27
b
 0.005 
JEJ 101.2 ± 6.22
ab
 110.2 ± 6.40
a
 89.7± 4.34
b
 0.065 
ILE 88.3 ± 3.11 90.7 ± 3.89 83.8 ± 3.68 0.4147 
           1 
Data are expressed as mean ± SEM 
           2 
Abbreviations:  FF, formula-fed; OPN, formula with OPN; SR, sow-reared; DUOD, duodenum; JEJ, jejunum; ILE, ileum 
           3
 Means within a row without a common letter differ at p < 0.05 
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      Table 2.4 Intestinal Disaccharidase Activity.
1,2,3
 
 
 
FF OPN SR p-value 
Lactase (μmol glucose/min/g protein) 
  DUOD 294.8± 18.69
b
 257.4 ± 13.94
b
 380.0 ± 17.25
a
 0.0005 
JEJ 645.4 ± 44.23
a
 562.3 ± 40.56
ab
 513.6 ± 38.12
b
 0.0219 
ILE 208.1 ± 10.16
a
 206.9 ± 15.39
a
 96.6 ± 12.92
b
 0.0002 
    Sucrase (μmol glucose/min/g protein) 
   DUOD 105.1 ± 12.19
b
 126.84 ±14.69
a,b
 173.7 ± 21.92
a
 0.0322 
JEJ 373.1 ± 18.58 330.1 ± 29.72 378.2 ± 27.86 0.3738 
ILE 73.7 ± 8.25
a
 87.9 ± 9.18
a
 46.7 ± 4.97
b
 0.0058 
         1 
Data are expressed as mean ± SEM 
         2 
Abbreviations:  FF, formula-fed; OPN, formula with OPN; SR, sow-reared; DUOD, duodenum; JEJ, jejunum; ILE, ileum 
         3
 Means within a row without a common letter differ at p < 0.05  
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Chapter 3 
Effect of Osteopontin on Serum Antibody Responses to Rotavirus Vaccination 
in Neonatal Piglets 
Abstract 
The objective of this study was to investigate whether supplemental osteopontin (OPN) 
influenced the serum antibody responses to rotavirus vaccination in neonatal piglets. Newborn, 
colostrum-deprived piglets were randomized into two dietary groups: formula with bovine OPN 
(OPN; 140 mg/L) and formula alone (FF) for 35 days. On d7, piglets in each dietary group were 
further randomized to receive rotavirus (RV) vaccination (Rotarix
®
) (FF+RV and OPN+RV) or 
remained non-vaccinated (FF+NV and OPN+NV). Booster vaccination was provided on d14. 
Blood samples were collected on d7, 14, 21, 28 and 35. RV-specific serum immunoglobulin (Ig) 
G, IgA, IgM and total serum IgG, IgA, IgM were measured by ELISA. Statistical significance 
was assigned at P<0.05, with trends reported as P<0.10. Body weight gain was unaffected by diet 
and/or vaccination. No significant effect of oral OPN supplementation was observed for RV-
specific antibody responses and total Igs levels. After the combination of dietary groups, RV 
piglets had significantly higher RV-specific IgM concentrations compared to NV piglets. 
Although there were higher means of RV-specific IgG and RV-specific IgA concentrations in 
RV group than their counterparts in NV group, the difference did not reach statistical 
significance. RV-specific IgM reached a peak at d7 post booster vaccination (PBV), whereas the 
RV-specific IgG and IgA peaked later at PBV 14 or 21. Total Igs were unaffected by RV 
vaccination but were significantly changed over time, following similar pattern as RV-specific 
Igs. In summary, neonatal piglets generated weak antibody responses to RV vaccination. 
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Supplemental OPN did not enhance RV-specific serum antibody responses and total serum Ig 
levels in neonatal piglets with or without RV vaccination.   
 
Introduction  
Osteopontin (OPN) is a multifunctional protein that is synthesized by a variety of 
nonimmune and immune cells and is involved in interactions with cells mediating signaling, 
migration, and attachment (Sodek et al., 2000). Within the immune system, OPN is a cytokine 
secreted by activated T cells, NK cells, dendritic cells, and macrophages during inflammatory 
processes (Kawamura et al., 2005; Sodek et al., 2006). Therefore, OPN plays a key role in the 
development and maintenance of immune responses (Wang and Denhardt, 2008). It has been 
shown to be an important early regulator of Th1-mediated immunity by inducing secretion of the 
Th1 cytokine IL-12 and inhibiting the production of the Th2 cytokine IL-10 (Ashkar et al., 2000). 
Moreover, it has recently shown that OPN acts as an opsonin that enhances bacterial 
phagocytosis (Schack et al., 2009).  
Schack and colleagues developed ELISAs (enzyme-linked immunosorbent assay) 
specific for OPN and measured its concentration in human milk, bovine milk and select infant 
formulas (Schack et al., 2009). They demonstrated that the OPN concentration in human milk is 
considerably higher than in bovine milk and infant formulas and that OPN levels in infant 
plasma were 10-fold higher than in adults. It was also found that milk OPN was able to induce 
IL-12 secretion from human lamina propria mononuclear cells (LPMNC) isolated from gut 
biopsies (Schack et al., 2009).  
Rotavirus (RV) is the most common viral cause of severe gastroenteritis in infants and 
young children worldwide (Parashar et al., 2006). The World Health Organization (WHO) 
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estimates that rotavirus diarrhea results in approximately half a million deaths and approximately 
2.4 million hospitalizations in developing countries each year (WHO, 2007). Osteopontin 
expression was up-regulated in the intestine of pigs following infection with Salmonella 
typhimurium or Salmonella choleraesuis (Burkey et al., 2006), providing support for a role of 
OPN in mediating host defense within the intestine. Additional findings in the literature using 
OPN null mice suggest that OPN modulates the gastrointestinal immune response in a dextran 
sulphate sodium (DSS)-induced colitis model (Da Silva et al., 2006) and following RV infection 
(Rollo et al., 2005). Taken together, these studies suggest that milk-borne OPN might be 
involved in host defense mechanisms of RV infection within in the neonate.  However, this 
remains to be proven in appropriate preclinical models and clinical studies.  
The determinants of protective active immunity to rotavirus are not well understood, but 
many reports indicate that serum anti-rotavirus immunoglobulins (Igs), especially IgA, were a 
marker of protection against rotavirus infection and moderate-to-severe diarrhea (Velazquez et 
al., 2000; Parreño et al., 1999).  
The piglet model has several advantages over other animal models for studies of 
immunity to human rotavirus (HRV). In comparison with mice and calves, the intestinal tract 
physiology, body size, type of passive immunity (milk IgA) and immune development of piglets 
resemble those of human infants more closely. Piglets are susceptible to HRV infection and 
produce subsequent diarrhea (up to 8 weeks or more after birth), which allows studies of the 
immune responses and the evaluation of vaccine efficacy with booster doses (Yuan et al., 2002). 
In addition, pigs are born devoid of maternal antibodies, acquiring serum Igs by intestinal 
absorption of colostrum Igs for up to 36 h after birth before gut closure (cessation of absorption 
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of intact Ig) occurs (Banks & McGuire, 1989), facilitating experimental manipulation of levels of 
maternal antibodies.  
Therefore, in our study, the colostrum-deprived piglets were utilized to determine the role 
of milk‐borne OPN in the host antibody responses to HRV vaccination. We hypothesized that 
OPN supplementation could enhance serum RV-specific antibody responses induced by HRV 
vaccination. In addition, serum Igs were measured as markers of systemic immune development.  
 
Materials and Methods  
 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise 
indicated.  
 
Study Design and Dietary treatments 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
at the University of Illinois. Newborn, colostrum-deprived piglets (n=24) were obtained by 
Cesarean section of term gestation sows (n=3), weighed, and littermates were randomized into 
two dietary groups: Formula alone (FF, n=12) or formula with OPN at 140 mg/L (OPN, n=12). 
Piglets were fed a nutritionally-complete commercial piglet formula (Advance Liquiwean, MSC, 
Dundee, IL) comprised of 25% protein, 13% fat, 48% lactose, 6.5% ash, and containing levels of 
vitamins, minerals, and trace elements to meet NRC requirements for piglets (NRC, 1998). To 
provide passive immunity, all piglets were orally gavaged with pregnant sow serum at the rates 
of 4ml, 5ml and 10 ml per kg body weight at 3, 12 and 22 hr postpartum, respectively (Sangild et 
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al, 2002). On d2 postpartum, piglets were administered 1ml of iron dextran (Durvet, Inc Blue 
Springs, MO) by intramuscular injection. Diets were prepared as 20% solids with the addition of 
double distilled water in a blender (200g/Liter). The bovine OPN was provided as a dried, 
purified powder by Arla Foods Ingr. (Vibjy P/S, Denmark).  The powder is ~ 83% purified OPN 
by weight.  It was diluted in double distilled water and was added to the formula immediately 
before feeding at a final concentration of 116 mg/L. Formula was offered at 21 times daily at an 
average rate of 13.8 ml/kg/h for the first 4 days and 17 ml/kg/h thereafter. Formula intake, stool 
consistency and activity scores were assessed daily (Correa-Matos et al., 2003). Formula not 
consumed by the piglet was recorded at each feeding in order to accurately determine the volume 
of formula consumed daily.  
On d7, piglets in each dietary group were further randomized to be vaccinated against 
rotavirus (FF+RV: n=6; OPN+RV: n=6) or non-vaccinated (FF+NV: n=6 or OPN+NV: n=6). 
RV piglets were orally given a clinically‐approved vaccine (Rotarix®, GlaxoSmithKline, 
Research Triangle Park, NC) at a dose of 1ml/piglet, which is the dose recommended for human 
infants. Booster vaccination (at the equal dose as the first vaccination) was orally administered 
on d14.  
 
Sample Collection  
Blood samples (2 ml) were collected on d7, 14, 21 and 28 by jugular puncture. The study 
was terminated at d35. Piglets were sedated with Telazol (Tiletamine HCl and Zolazepam HCl, 
3.5mg/kg BW each, Pfizer Animal Health, Fort Dodge, IA) and then euthanized by an 
intracardiac injection of sodium pentobarbital (Fatal Plus, Vortech Pharmaceuticals, Dearborn, 
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MI; 72mg/kg body weight). Final blood samples were collected by cardiac puncture into heparin-
laced vials and serum was separated by centrifugation.  
 
Assessment of RV-Specific Antibody Responses 
To determine isotype-specific antibody titers to RV vaccination in serum samples, three 
ELISAs were developed in our laboratory.  
RV-Specific Serum IgG ELISA. 96-well ELISA plates were coated with 1:400 dilution 
of crude OSU RV solution (generously provided by Dr. Theresa Kuhlenschmidt, Department of 
Pathobiology, College of Veterinary Medicine, University of Illinois) in Carb/Bicarb buffer (pH 
9.6) overnight at 4 °C. The assay was completed the next day at room temperature. The next day, 
plates were blocked with PBS/3% BSA (Sigma, St. Louis, MO) solution for 1 hr followed by 
washing 3 times with 0.1% Tween 20/PBS. Next, serum samples diluted in 0.5% fish 
gelatin/PBS were added and incubated for 1 hr. Plates were washed as before. Goat anti-pig IgG 
conjugated to horseradish peroxidase (HRP, Bethyl Labs, Montgomery, TX) was then added at 
1:20,000 dilution and incubated for 1 hr, followed by washing 4-times. TMB (BD Biosciences, 
San Jose, CA) was added and incubated in the dark for 25 min. Finally, 2N sulfuric acid was 
added and plates were read at 450nm on a SpectraMax M2e (Molecular Devices, Sunnyvale, CA) 
with 570 nm plate correction wavelength. RV-specific IgG concentration of each sample was 
calculated using a standard curve created form stock RV-positive serum.  The antibody 
concentrations for the points on the standard curve were set as the reciprocal of the dilution 
factor multiplied by 1000.  For instance, the 1:100 point on the standard curve is reported as 10.  
RV-Specific Serum IgA ELISA. 96-well ELISA plates were coated with 5 µg/ml goat 
anti-pig IgA (Bethyl Labs) in Carb/Bicarb buffer (pH 9.6) overnight at 4 °C. The assay was 
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completed the next day at room temperature. Plates were blocked, diluted serum samples were 
added and incubated as indicated in rotavirus specific IgG ELISA. Biotinylated pig OSU strain 
RV (see below) at a dilution of 1:1000 in 0.5% fish gelatin/PBS was added and incubated for 1 
hr, followed by washing 3 times with 0.1% Tween 20/PBS. Streptavidin-conjugated horse radish 
peroxidase (S-HRP, R&D systems, Minneapolis, MN) diluted 1:200 in 0.5% fish gelatin/PBS 
was added and incubated for 1 hr, followed by washing 4 times. Finally, TMB (BD Biosciences) 
was added and incubated in the dark for 20 min, followed by adding sulfuric acid and reading 
plates as described in RV-specific IgG ELISA. RV-specific IgA concentration of each sample 
was calculated using a standard curve created form stock serum. The antibody concentrations for 
the points on the standard curve were set as described above.  
RV-Specific Serum IgM ELISA. 96-well ELISA plates were coated with 10 µg/ml goat 
anti-pig IgM (Bethyl Labs) in Carb/Bicarb buffer (pH 9.6) overnight at 4 °C. The assay was 
completed the next day at room temperature. Plates were blocked, diluted serum samples were 
added and incubated as indicated in rotavirus specific IgG ELISA. Biotinylated pig OSU strain 
RV (see below) at a dilution of 1:5000 in 0.5% fish gelatin/PBS was added and incubated for 1 
hr, followed by washing 3 times with 0.1% Tween 20/PBS. S-HRP (R&D systems) diluted 1:200 
in 0.5% fish gelatin/PBS was added and incubated for 1 hr, followed by washing 4-times. Finally, 
TMB (BD Biosciences) was added and incubated in the dark for 35 min, followed by adding 
sulfuric acid and reading plates as described in RV-specific IgG ELISA. RV-specific IgM 
concentration of each sample was calculated using a standard curve created form stock serum. 
The antibody concentrations for the points on the standard curve were set as described above.  
Biotin-labeling of RV-Biotin. Crude OSU RV solution (generously provided by Dr. 
TheresaKuhlenschmidt, Department of Pathobiology, College of Veterinary Medicine, 
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University of Illinois) was first dialyzed against PBS using 3500 molecular weight cutoff dialysis 
tubing (Fisher Scientific, Pittsburgh, PA). This dialyzed sample was then incubated with 20mM 
NHS-PEG4-biotin (Pierce, Thermo Fisher Scientific, Rockford, IL) for 2 hr on ice. Biotinylated 
sample was dialyzed against PBS as above. Resulting RV-biotin was tested by coating a 96-well 
ELISA plate with the RV-biotin sample and detecting with S-HRP (R&D systems) using TMB 
(BD Biosciences). Non biotinylated RV was used as negative control.  
Total serum immunoglobulin levels 
Total serum immunoglobulin levels were detected by ELISA using commercially-
available porcine IgG, IgA, and IgM Quantitation Sets (Bethyl Labs).  
Total Serum IgG ELISA. 96-well ELISA plates were coated with 1:100 dilution of 
Affinity purified Pig IgG (A100-104A) Coating Antibody in Carb/Bicarb buffer (pH 9.6) 
overnight at 4 °C. The assay was completed the next day at room temperature. Plates were 
blocked; diluted serum samples were added and incubated as indicated in RV-specific IgG 
ELISA. The HRP Conjugated Pig IgG Detection Antibody (A100-104P) at a dilution of 1:75,000 
in 0.5% fish gelatin/PBS was added and incubated for 1 hr, followed by washing 3 times with 0.1% 
Tween 20/PBS. Finally, TMB (BD Biosciences) was added and incubated in the dark for 15 min, 
followed by adding sulfuric acid and reading plates as described in RV-specific IgG ELISA. 
Total IgG concentration of each sample was calculated using a standard curve created form Pig 
Reference Serum (RS10-107). Each of standard curve point is listed as 10,000 ng/ml, 500 ng/ml, 
250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml,7.8 ng/ml and 0 ng/ml (blank).  
Total Serum IgA ELISA. 96-well ELISA plates were coated with 1:100 dilution of 
Affinity purified Pig IgA Coating Antibody (A100-102A) in Carb/Bicarb buffer (pH 9.6) 
overnight at 4 °C. The assay was completed the next day at room temperature. Plates were 
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blocked; diluted serum samples were added and incubated as indicated in RV-specific IgG 
ELISA. The HRP Conjugated Pig IgA Detection Antibody (A100-102P) at a dilution of 1:75,000 
in 0.5% fish gelatin/PBS was added and incubated for 1 hr, followed by washing 3 times with 0.1% 
Tween 20/PBS. Finally, TMB (BD Biosciences) was added and incubated in the dark for 15 min, 
followed by adding sulfuric acid and reading plates as described in RV-specific IgG ELISA. 
Total IgA concentration of each sample was calculated using a standard curve created form Pig 
Reference Serum (RS10-107). Each of standard curve point is listed as 1000 ng/ml, 500 ng/ml, 
250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml, and 0 ng/ml (blank). 
Total Serum IgM ELISA. 96-well ELISA plates were coated with 1:100 dilution of 
Affinity purified Pig IgM Coating Antibody (A100-100A) in Carb/Bicarb buffer (pH 9.6) 
overnight at 4 °C. The assay was completed the next day at room temperature. Plates were 
blocked; diluted serum samples were added and incubated as indicated in rotavirus specific IgG 
ELISA. The HRP Conjugated Pig IgM Detection Antibody (A100-100P) at a dilution of 
1:75,000 in 0.5% fish gelatin/PBS was added and incubated for 1 hr, followed by washing 3 
times with 0.1% Tween 20/PBS. Finally, TMB (BD Biosciences) was added and incubated in the 
dark for 15 min, followed by adding sulfuric acid and reading plates as described in rotavirus 
specific IgG ELISA. Total IgM concentration of each sample was calculated using a standard 
curve created form Pig Reference Serum (RS10-107). Each of standard curve point is listed as 
1000 ng/ml, 500 ng/ml, 250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml, and 0 ng/ml 
(blank). 
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Statistical Analyses 
All data are expressed as mean ± standard error of the mean. Antibody titers were 
analyzed using Proc Mixed procedure with repeated measures. In the complete statistical model, 
the fixed effects were diet, vaccination, time and their interactions. If dietary effect was not 
significant, the OPN + RV and FF + RV piglets were combined as a single RV vaccination (RV) 
group; OPN+NV and FF+NV were combined as a single non-vaccinated (NV) group. Post hoc t-
tests with Tukey correction were utilized in the event of significant vaccine x time interactions. 
A one-way ANOVA was used to evaluate the antibody concentrations over time. Analyses were 
performed using SAS Version 9.2 (SAS Institute, Cary, NC). Statistical significance was 
assigned at P < 0.05, with trends reported as P<0.10.    
 
Results  
 
Mortality Rate   
This was the first RV vaccination study conducted in colostrum-deprived piglet model in 
our laboratory. Since colostrum-deprived piglets were extremely susceptible to environmental 
pathogens, 41.6% (10/24) piglets died prior to euthanasia and of those piglets that died, 90% 
(9/10) died during the first two weeks postpartum. At the termination of the study, blood samples 
were collected from each of the following groups: FF+RV (n=4), FF+NV (n=2), OPN+RV (n=5) 
and OPN+NV (n=3).  
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Body Weight Gain   
There was no effect of OPN (P=0.71) or vaccination (P=0.41) on body weight gain. Since 
there was no dietary effect, OPN+NV and FF+NV were combined as a single non-vaccinated 
(NV) group. The average body weight gain for OPN+RV, FF+RV and NV was 6.80 ± 0.55 kg, 
7.18 ± 0.27 kg and 7.48 ± 0.53 kg, respectively (Figure 3.1).  
 
Immunoglobulin Levels in Pregnant Sow Serum 
In order to determine the effects of pre-feeding sow serum in antibody responses, RV-
specific Igs and total Igs concentrations were measured in sow serum that was orally-
administered to the piglets (Table 3.1). RV-specific IgG concentrations (Table 3.1A) in sow 
serum were 8-fold higher compared to the average concentrations of the peak antibody responses 
(d35) in piglets’ serum. However, RV-specific IgA and IgM levels in sow serum were 7% and 15% 
of the average levels of the peak antibody response (d28 or d21) in piglets’ serum, respectively. 
The relationship among total IgG, total IgA and total IgM was 80%, 2%, 17% of the total Ig 
concentrations (Table 3.1B), which was in the normal range of sow serum Igs levels during early 
gestation (Klobasa et al., 1985). The total serum IgG percentage was also comparable to its 
counterpart in sow colostrum (Markowska-Daniel & Pomorska-Mol, 2010).  
 
Total Serum Immunoglobulin levels   
In order to determine the dietary and/or vaccination effects on systemic immune 
development in piglets, serum samples were analyzed for IgG, IgA and IgM concentrations on 
day 7, day 14, day 21, day 28 and day 35. The average of total serum Igs concentrations from 
four groups were summarized in Figure 3.5. Concentrations of total IgG, IgA and IgM in the 
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sera of all four treatment groups (FF and OPN, both V and NV) are summarized in Appendix 
Tables 1-3, respectively.  
 
 Total Serum IgG.  No effect of OPN (P=0.71), RV vaccination (P=0.07) or OPN × RV 
vaccination (P=0.88) was observed in the complete model. The only significant effect was time 
(P=0.0006). After the combination of the dietary groups, the effect of RV vaccination tended to 
reach statistical significance (P=0.05). Between day 7 to day 35, total IgG concentrations in RV 
group were increased (P<0.0001) over time (Figure 3.2).  
. 
Total Serum IgA.  No effect of OPN (P=0.85), RV vaccination (P=0.31) or OPN × RV 
vaccination (P=0.92) was observed in the complete model. The only significant effect was time 
(P<0.0001). After the combination of the dietary groups, the effect of RV vaccination was still 
not significant (P=0.26). Between day 7 to day 35, total IgA concentrations were changed 
(P<0.0001) over time and peaked on day 28 (Figure 3.3). 
 
Total Serum IgM.  No effect of OPN (P=0.73), RV vaccination (P=0.13) or OPN × RV 
vaccination (P=0.32) was observed in the complete model. The only significant effect was time 
(P<0.0001). After the combination of the dietary groups, the effect of RV vaccination tended to 
reach statistical significance (P=0.10). Between day 7 to day 35, total IgM concentrations were 
changed (P<0.0001) over time and peaked on day 14 (Figure 3.4).  
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Assessment of RV-Specific Antibody Responses   
To evaluate the effects of oral OPN supplementation on RV-specific antibody responses, 
RV-specific IgG, IgA and IgM concentrations were measured on day 7, day 14, day 21, day 28 
and day 35. Antibody Titers of RV-specific IgG, IgA and IgM in the sera of all four 
treatment groups (FF and OPN, both V and NV) are summarized in Appendix Tables 4-6, 
respectively.  
 
    RV-Specific Serum IgG.  No effect of OPN (P=0.82), RV vaccination (P=0.35) or OPN × 
RV vaccination (P=0.99) was observed in the complete model. The only significant effect was 
time (P<0.0001). Since there was no dietary effect, the OPN + RV and FF + RV piglets were 
combined as a single rotavirus vaccination (RV) group; OPN+NV and FF+NV were combined as 
a single non-vaccinated (NV) group (Same below). The effect of RV vaccination was still not 
significant (P=0.29). RV-specific IgG concentrations increased over time in both groups 
(P<0.0001). Between day 7 to day 35, RV piglets had 6.8-fold increase in RV-specific IgG, 
while NV piglets had 5.3-fold increase in RV-specific IgG (Figure 3.6). 
 
 RV-Specific Serum IgA.  On day 7, RV-specific IgA concentrations were low to 
undetectable. No effect of OPN (P=0.75), RV vaccination (P=0.53) or OPN × RV vaccination 
(P=0.92) was observed in the complete model. The only significant effect was time (P=0.0004). 
After the combination of the dietary groups, the effect of RV vaccination was still not significant 
(P=0.48). RV-specific IgA concentrations were increased (P<0.0001) over time (Figure 3.7).  
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 RV-Specific Serum IgM.  No effect of OPN (P=0.97) or OPN × RV vaccination (P=0.56) 
was observed in the complete model. The only significant effect was time (P<0.0001). After the 
combination of the dietary groups, the effects of RV vaccination (P=0.02), time (P<0.0001) and 
RV vaccination × time (P=0.02) were significant. Although 85% d7 piglets had undetectable 
RV-specific IgM, d14 RV piglets had 5.8-fold higher (P=0.0064) RV-specific IgM levels 
compared to d14 NV piglets. RV-specific IgM titers were changed (P<0.0001) over time and 
peaked on day 21 within each group (Figure 3.8).  
 
Discussion  
 
Milk‐borne OPN may be important for pediatric nutrition for a variety of reasons. It is a 
multifunctional protein that is involved in both physiologic and pathological events, including 
cell mediated immune responses (Ashkar et al., 2000), chemotaxis of inflammatory cells 
(Giachelli et al.,1998) and anti‐inflammatory responses (Hwang et al., 1994). Concerning the 
role of OPN in immune responses, it has been described that OPN polarizes the Th-1-related 
cytokine response and contributes to protective immunity against pathogens, such as herpes 
simplex virus type 1 and L. monocytogenes (Ashkar et al., 2000; Nau et al., 1999). Pabst and 
colleagues (1989) reported that breast‐fed infants showed an increased proliferative response of 
T‐lymphocytes compared to formula‐fed infants following vaccination with Mycobacterium 
bovus bacillus Calmette‐Guerin (BCG) at birth. A potential role for OPN in mediating host 
response is corroborated by the observation that BCG grew more rapidly in macrophages 
derived from OPN‐null versus wild‐type mice (Nau et al., 1999). Furthermore, an inverse 
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correlation between tissue OPN expression and disease progression was observed after 
inoculation with BCG in human subjects (Nau et al., 2000). 
Rotaviruses are an important cause of severe acute gastroenteritis, a self-limited illness 
that may cause fatal volume depletion in young children. The immune response engendered in 
the host is important to limit future infections, but has limited impact on the acute illness. A 
variety of other host responses to infection mediate the amelioration of the infection and/or 
symptoms. It has been shown that increased production and secretion from intestinal epithelial 
cells of osteopontin occurs in response to infection with rotavirus (Rollo et al., 2005). Serum 
antibodies are an important and powerful correlate of protection against rotavirus disease (Jiang 
et al., 2002). Therefore, the objective of this study was to determine the role of OPN in serum 
antibody response (RV-specific IgG, IgA, IgM) and total Igs levels (total IgG, IgA, IgM) 
induced by RV vaccination in colostrum-deprived piglets.  
Overall, our piglet model (colostrum-deprived, orally serum-gavaged) generated weak 
antibody response to RV vaccination. The only relatively robust antibody response was shown in 
RV-specific IgM. At d7 post first vaccination, it was found that RV piglets had significantly 
higher (5.8-fold) RV-specific serum IgM concentrations compared to NV piglets. At d14 post 
first vaccination, although RV piglets had higher means of RV-specific IgG (2-fold) and IgA 
(1.2-fold) concentrations compared with NV piglets, the difference did not reach statistical 
significance. Because of the small number of piglets available in each group and the degree of 
variability of vaccination responses in piglets, it was not feasible to statistically evaluate our data. 
However, the following patterns were evident. RV-specific IgM reached a peak at d7 post 
booster vaccination (PBV), whereas the RV-specific IgG and IgA peaked later at PBV 14 or 21. 
This kinetics of RV-specific antibody responses in RV group were consistent with other studies 
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in which piglets were inoculated with porcine RV or HRV using an ELISPOT assay (Chen et al., 
1995; Yuan et al., 1996). Although following the similar pattern, NV group generated weaker 
RV-specific antibody responses. This suggested a possibility of naturally asymptomatic infection 
induced by RV in the rearing environment, which is also common in children under two-years-
old (Phillips et al., 2010). 
Rotarix
®
 is a monovalent vaccine composed of an attenuated human rotavirus strain 
G1P[8]. Three clinical trials involving 5024 infants conducted in Finland, Latin America and 
Singpore indicated a good immunogenicity of this vaccine (De Vos et al., 2004). Many reports 
indicate that serum IgA antibodies are important for immunity to rotavirus and resistance to 
symptomatic re-infection (Yuan et al., 1996; Johansen & Svensson, 1997). In the 3 trials, 61–91% 
of vaccinated infants developed rotavirus-specific serum IgA antibodies after 2 doses, depending 
on Rotarix® potency (De Vos et al., 2004). In a recent trial conducted in healthy Indian infants, 
Rotarix® increased RV-specific IgA concentrations more than two-fold in 60.5% of infants, 
while 7.5% of placebo recipients showed a two-fold increase (Narang et al., 2009). However, 
robust RV-specific IgA response was not observed in our study. In oral rotavirus vaccine trials 
conducted in humans, higher pre-vaccination antibody titers in serum have been associated with 
lower rates of seroconversion after vaccination (Friedman et al., 1993; Ward et al., 1997). 
Parreño et al. (1999) reported that higher titers of circulating maternal antibodies  
(MatAb) suppressed primary and secondary active antibody response significantly. For a study 
of  the attenuated human RV vaccine/ RV-like particles (VLP) vaccine, there was evidence for 
suppression of systemic antibody responses by LoMatAb, especially systemic IgA ASC, IgA 
memory B cells in peripheral blood and serum IgA antibody responses (Nguyen et al., 2006). 
Thus, the sow serum with relatively low titers of MatAb used in our current study, although 
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contributing to passive immunity against environmental pathogens in piglets, may impair the 
development of active immunity and decrease the efficacy of live oral rotavirus vaccines. It is 
possible that high titers of IgG maternal antibodies in piglets’ serum were associated with 
suppressing primary and secondary responses of RV-specific IgA after inoculation (Parreño et al., 
1999).   
To gain a perspective of dietary and/or vaccination effects on systemic immune 
development in piglets, total serum Igs concentrations were analyzed in our study. It was found 
that total serum IgG levels were much lower than their counterparts in sow-reared (SR) piglets 
reported in previous research (Bourne et al., 1973). This is not surprising, since our piglets were 
colostrums-deprived and colostrum is characterized by a high concentration of IgG and relatively 
lower concentration of IgA and IgM (Markowska-Daniel & Pomorska-Mol, 2010). According to 
Klobasa’s research (1981), the IgA concentrations in the serum of naturally sucking piglets 
varied in the first 24 hours but then decreased rapidly to their lowest values (≈200µg/ml) around 
14~28 day of age, whereas the IgM concentrations decreased rapidly following the first 24 hours 
of life to their lowest levels (~600µg/ml) around 8~14 day of age. In the contrast, our study 
showed that IgA concentrations peaked at day 28 of age and 4.5-fold (RV group) or 3.4-fold (NV 
group) higher than their counterparts in naturally sucking piglets. Furthermore, IgM 
concentrations peaked at day 14 of age and were 1.7-fold (RV group) or 1.3-fold (NV group) 
higher than their counterparts in naturally sucking piglets. This phenomenon suggests a possible 
RV vaccination responses and/or naturally asymptomatic RV infection.  
Piglet’s antibody responses to RV vaccination varied widely in our study. At d7 post first 
vaccination, only 66% and 44% of RV piglets showed RV-specific IgG and RV-specific IgA 
responses. Piglets' immune responses to a live oral vaccine may be influenced by the amount of 
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gastric acid in the piglets’ digestive tract. Rotavirus can be damaged by low pH in the stomach, 
and each of the vaccines is administered with a buffer solution to neutralize stomach acid and 
maintain the titer of the virus. Considering the large discrepancy in the effectiveness of rotarix in 
infants among developed and developing countries (Patel et al., 2009), it is very likely that a 
difference in levels of gastric acidity might have influence on vaccine uptake and inducing 
immune responses. Furthermore, the booster vaccination triggered much lower RV-specific IgA 
(54%) and IgM (44%) response than the first vaccination did. Nguyen et al. (2005) demonstrated 
in a RV vaccine study of gnotobiotic piglets that oral priming and intranasal boosting strategies 
were highly effective in inducing antibody responses. This strategy of avoiding mucosal sites 
where booster vaccines may be neutralized by local antibodies induced by the priming vaccine 
assures that booster vaccination will evoke effective antigenic stimulation. Piglets were also 
received 5ml of 100 μM sodium bicarbonate to reduce stomach acidity followed by the oral 
vaccines.  
In the present study, supplemental OPN had no effect on the improvement of antibody 
responses and total Igs levels in neonatal piglets after RV vaccination. Therefore, the role of 
OPN in RV vaccination is still inconclusive. However, there is increasing evidence that this 
protein is involved in many aspects of intestinal physiology in health and disease. Since the 
existence of OPN in breast milk as well as intestinal epithelial cells (Sodek et al., 2000), OPN in 
the intestinal lumens of suckling mice consists of OPN in breast milk and from intestinal 
epithelial cells. The constitutive expression of OPN by epithelial cells is required for maintaining 
the epithelial barrier in the intestines (Gassler et al., 2002). OPN also has the potential to regulate 
specific functions of epithelial cells involved in the barrier defense process (Sodek et al., 2006). 
OPN, moreover, is recognized by αvβ3 and α4β1 integrins as ligands of the cell adhesion domain 
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(Bayless, 1998; Sodek et al., 2000). These integrins are also known as receptors for RV entry 
into cells (Guerrero et al., 2000; Hewish et al., 2000). These pieces of evidence suggest that OPN 
may inhibit RV attachment or entry into cells. In addition, another study has demonstrated that 
OPN knockout (OPN-KO) suckling mice were more susceptible to RV infection and showed 
prolonged diarrhea duration compared to wild-type (WT) suckling mice (Maeno et al., 2009). On 
d2 post infection, mRNA levels of interleukin-1β, tumor necrosis factor-α, and interleukin-15 in 
OPN-KO mice were lower than in WT mice, although mRNA expression of Th-1 and Th-2 
related cytokines in the small intestine were nearly the same between OPN-KO and WT mice 
(Maeno et al., 2009). Taken together, these findings suggested that OPN is involved in innate 
responses against RV infection. Innate limitations by OPN on rotavirus infection may include the 
elaboration by the host of protective factors that ameliorate the severity of the infection or speed 
mucosal repair (Rollo et al., 2005). The importance of innate responses of the host has long been 
recognized because children in the acute stage of typical RV infection do not develop sufficient 
RV-specific T cells or antibodies that are needed to overcome infections (Bhan et al., 1993; Jiang 
et al., 2002). Rotarix
®
, a live, attenuated rotavirus vaccine, mimics natural infection and 
stimulates robust humoral immune responses. Therefore, OPN might have no beneficial effect on 
antibody responses and total Igs levels to RV vaccination.  
In summary, this study demonstrated that supplemental OPN did not enhance the RV-
specific antibody responses (RV-specific IgG, IgA, IgM) and total Igs concentrations (total IgG, 
IgA, IgM) in neonatal piglets with or without RV vaccination. Since neonatal piglets generated 
weak antibody responses to RV vaccination, additional studies are needed to investigate the 
effects of OPN supplementation on immune responses to other types of vaccine that piglets will 
not have exposure to via colostrum. 
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Figure 3.1 Body weight gain. There was no effect of OPN (P=0.71) or vaccination (P=0.41) on body weight 
gain. Since there was no dietary effect, OPN+NV and FF+NV were combined as a single non-vaccinated (NV) 
group. The average body weight gain for OPN+RV, FF+RV and NV was 6.80 ± 0.55 kg, 7.18 ± 0.27 kg and 7.48 
± 0.53 kg, respectively. Values are expressed as mean ± SEM. 
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Figure 3.2 Total serum IgG concentrations in piglets with (RV) or without RV (NV) vaccination. Serum samples 
were collected on day 7, 14, 21, 28 and 35. After the combination of dietary groups, the effect of RV vaccination tended 
to reach statistical significance (P=0.05). Between day 7 to day 35, total IgG concentrations in RV group were increased 
(P<0.0001), ranging from 539 ±107 µg/ml (day 7) to 1237±176 µg/ml (day 35), while total IgG concentrations in NV 
group were also increased (P=0.0002), ranging from 511±85 µg/ml (day 7) to 950±158 µg/ml (day 35). Values are 
expressed as mean ± SEM. abc Values over time lacking a common letter differ at P<0.05. 
89 
 
 
 
         
 
Figure 3.3 Total serum IgA concentrations in piglets with (RV) or without RV (NV) vaccination. Serum 
samples were collected on day 7, 14, 21, 28 and 35. After the combination of dietary groups, the effect of RV 
vaccination was still not significant (P=0.26). Between day 7 to day 35, total IgA concentrations were changed 
(P<0.0001) over time and peaked on day 28. Values are expressed as mean ± SEM. abc Values over time lacking a 
common letter differ at P<0.05. 
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Figure 3.4 Total serum IgM concentrations in piglets with (RV) or without RV (NV) vaccination. Serum 
samples were collected on day 7, 14, 21, 28 and 35. After the combination of dietary groups, the effect of RV 
vaccination tended to reach statistical significance (P=0.10). Between day 7 to day 35, total IgM concentrations were 
changed (P<0.0001) over time and peaked on day 14. Values are expressed as mean ± SEM. abc Values over time 
lacking a common letter differ at P<0.05. 
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Figure 3.5 Total serum immunoglobulin concentrations in neonatal piglets. Serum samples were 
collected on day 7, 14, 21, 28 and 35. This figure illustrates the pattern of immunoglobulins in the serum 
of piglets over the first 5 weeks of life.  
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Figure 3.6 RV-specific serum IgG concentrations in piglets with (RV) or without RV (NV) vaccination. Serum 
samples were collected on day 7, 14, 21, 28 and 35. After the combination of dietary groups, the effect of RV vaccination 
was still not significant (P=0.29). RV-specific IgG concentrations increased (P<0.0001) over time. Between day 7 to day 
35, RV piglets had 6.8-fold increase in RV-specific IgG, while NV piglets had 5.3-fold increase in RV-specific IgG. Values 
are expressed as mean ± SEM. abc Values over time lacking a common letter differ at P<0.05. 
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Figure 3.7 RV-specific serum IgA concentrations in piglets with (RV) or without RV (NV) vaccination. Serum 
samples were collected on day 7, 14, 21, 28 and 35. After the combination of dietary groups, the effect of RV vaccination 
was still not significant (P=0.48). All of d7 piglets had undetectable RV-specific IgA levels. RV-specific IgA 
concentrations were increased (P<0.0001) over time. Values are expressed as mean ± SEM. abc Values over time lacking a 
common letter differ at P<0.05. 
94 
 
 
 
 
 
 
 
 
RV-Specific Serum IgM  
Figure 3.8 RV-specific serum IgM concentrations in piglets with (RV) or without RV (NV) vaccination. Serum 
samples were collected on day 7, 14, 21, 28 and 35. After the combination of the dietary groups, the effects of RV 
vaccination (P=0.02), time (P<0.0001) and RV vaccination × time (P=0.02) were significant. RV-specific IgM titers 
were changed (P<0.0001) over time and peaked on day 21 within each group. Values are expressed as mean ± SEM. abc 
Values over time lacking a common letter differ at P<0.05. 
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       Table 3.1 Immunoglobulin Levels in Pregnant Sow Serum. 
 
A. RV-specific immunoglobulins titers 
 
 
 
Arbitrary Titer 
 
RV-Specific IgG RV-Specific IgA RV-Specific IgM 
 
Sow serum 
 
16573 58 972 
 
Peak Antibody Titers 
 
2018 837 6349 
 
Ratio 
 
8 7% 15% 
    
 
B. Total immunoglobulins concentrations 
 
(µg/ml) 
 
Total IgG Total IgA Total IgM 
 
Sow Serum 
 
42904 1438 9162 
 
Ratio 
 
80% 2% 17% 
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Chapter 4 
Conclusions and Future Directions 
 
These studies focused on furthering our understanding of the effects of osteopontin (OPN) 
on intestinal development and serum antibody responses to rotavirus (RV) vaccination in 
neonates. In Chapter 2, piglet intestinal development was evaluated by measuring intestinal 
weight and length, mucosal protein and DNA content, disaccharidase activity, villus morphology 
and jejunal enterocyte proliferation. Overall, OPN supplementation in formula exerts minor 
effects within the small intestine. Bovine OPN added formula at human milk concentrations did 
not appear to significantly affect intestinal structural and functional development in neonatal 
piglets.  
The biological activity of a purified protein is an important consideration when assessing 
its biological function.  In milk, OPN is present as an intact protein or in several proteolytically 
generated N- and C-terminal fragments (Sørensen and Petersen, 1993b; Sørensen et al., 2003). 
Since there is currently no antibody against porcine OPN available, we were unable to measure 
the concentration of OPN in either sow milk or piglet serum. Thus, the OPN intake of the SR 
piglets from sow milk is unknown.  In addition, whether serum OPN concentrations were higher 
in OPN compared to FF piglets could not be assessed. However, OPN purified from bovine milk 
was shown to induce IL-12 expression in cultured human intestinal mononuclear cells (Schack et 
al. 2009). This is further supported by the observation that bovine milk OPN was partially 
resistant to proteolysis by neonatal gastric juice (Chatterton et al., 2004).  These studies suggest 
that the purified protein retains its bioactivity; however, further studies are needed to determine 
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whether supplemental bovine OPN survives digestion in vivo and is absorbed into the piglet 
circulation.  
Previous work from our laboratory has shown that the supplementation of OPN to 
formula at human milk concentrations decreased the differences in jejunal gene expression 
between formula-fed and mother-fed Rhesus monkeys (Donovan et al., 2011). Differences in 
signaling pathways regulating stem cell proliferation (WNT), gastrointestinal patterning 
(HEDGEHOG) and cell fate between secretory and absorptive lineages (NOTCH) were 
differentially expressed among the groups. Consequently, future work could identify gene 
expression in the jejunum of these piglets using gene microarray to determine whether 
supplemental OPN is also modulating the intestinal transcriptome of piglets.  
The objective of Chapter 3 was to investigate whether supplemental OPN influenced the 
serum antibody responses to rotavirus vaccination (Rotarix
®
, a live attenuated rotavirus vaccine, 
mimics natural infection and stimulates humoral immune responses.)
 
in neonatal piglets. Our 
results suggested that supplemental OPN had no effect on RV-specific serum antibody responses 
and total serum Ig levels in neonatal piglets. This may alternatively support previous findings 
that OPN is involved in innate responses against RV infection. Innate limitations by OPN on RV 
infection may include the inhibition of RV attachment or entry into cells or regulation of 
epithelial restitution (Rollo et al., 2005). A recent study has shown that ingested OPN decreased 
necrotising enterocolitis (NEC) severity (Møller et al., 2011). Therefore, the potential 
mechanisms of innate immune function of OPN against RV vaccination or infection remains to 
be elucidated in future studies. 
Overall, our piglet model (colostrum-deprived, orally serum-gavaged) generated weak 
antibody response to RV vaccination. Many reports indicate that RV-specific serum 
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immunoglobulins (Igs), especially IgA, were a good marker of protection against RV infection 
and moderate-to-severe diarrhea (Velazquez et al., 2000; Parreño et al., 1999). However, robust 
RV-specific IgA response was not observed in our study. Intestinal IgA antibody and fecal IgA 
antibody are better correlates of protection from RV infection (Brown et al., 2000).  Large-size 
animal studies are needed to extend our results by measuring RV-specific IgA, IgG, IgM 
concentrations in intestinal fluid or feces. To evaluate the effector B cell and memory B cell 
responses, ELISPOT assays could be used to enumerate RV-specific antibody secreting cell 
(ASC) of different isotypes (IgA, IgG and IgM). 
In addition, the weak antibody responses to RV vaccination suggested that the sow serum 
with maternal antibodies used in our study, although protecting piglets against environmental 
pathogens, may impair the development of active immunity and decrease the efficacy of live oral 
rotavirus vaccines. To further investigate the immunological roles of OPN, an influenza 
(Fluzone
™
) vaccination piglet study with OPN supplementation could be conducted to determine 
the effects of OPN in the development of vaccine-induced antibody responses. Previous work 
from our laboratory demonstrated that Fluzone
™
 vaccination induced robust antibody responses. 
Therefore, it is possible to assess the role of bovine OPN in the development of infants' immune 
responses to influenza vaccination.  
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Appendix A: Supplemental Tables 
 
 
      Table A.1. Effect of Dietary Treatment and Vaccination on Total Serum IgG.1,2,3 
 
 
 Day 7 Day 14 Day 21 Day 28 Day 35 
 
FF + RV 
 
542 ± 83 678 ± 104 942 ± 145 1359 ± 209 1396 ± 215 
 
OPN + RV 
 
536 ± 75 762 ± 109 985 ± 140 1147 ± 164 1109 ± 158 
 
FF + NV 
 
557 ± 92 407 ± 66 581 ± 95 880 ± 147 951 ± 158 
 
OPN + NV 
 
466 ± 77 535 ±89 509 ± 84 755 ± 126 949 ± 158 
 
 
 
 
 
    
 
 
 
 
 
 
 
1 Data are expressed as mean ± SEM 
2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; NV, non-vaccinated; V, vaccinated with Rotarix® 
3 In the complete model, no effect of OPN (P=0.71), RV vaccination (P=0.07) or OPN × RV vaccination (P=0.88) 
was observed. The only significant effect is time (P=0.0006).  
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     Table A.2.  Effect of Dietary Treatment and Vaccination on Total Serum IgA.1,2,3 
 
 
 Day 7 Day 14 Day 21 Day 28 Day 35 
 
FF + RV 
 
33 ± 4 496 ± 70 753 ± 107 912 ± 130 670 ± 93 
 
OPN + RV 
 
47 ± 7 309 ± 45 818 ± 120 908 ± 133 624 ± 91 
 
FF + NV 
 
49 ± 9 235 ± 42 588 ± 106 701 ± 127 636 ± 115 
 
OPN + NV 
 
51 ± 8 236 ± 43 651 ± 118 666 ± 121 554 ± 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Data are expressed as mean ± SEM 
2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; NV, non-vaccinated; V, vaccinated with Rotarix® 
3 In the complete model, no effect of OPN (P=0.85), RV vaccination (P=0.31) or OPN × RV vaccination (P=0.92) was 
observed. The only significant effect is time (P<0.0001).  
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     Table A.3.  Effect of Dietary Treatment and Vaccination on Total Serum IgM.1,2,3 
 
 
 Day 7 Day 14 Day 21 Day 28 Day 35 
 
FF + RV 
 
81 ± 11 903 ± 129 487 ± 69 361 ± 51 265 ± 38 
 
OPN + RV 
 
84 ± 11 1105 ± 162 605 ± 89 395 ± 58 253 ± 38 
 
FF + NV 
 
71 ± 10 779 ± 120 287 ± 44 270 ± 54 284 ± 43 
 
OPN + NV 
 
68 ± 10 728 ± 112 360 ± 55 216 ± 21 221 ± 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Data are expressed as mean ± SEM 
2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; NV, non-vaccinated; V, vaccinated with Rotarix® 
3 In the complete model, no effect of OPN (P=0.74), RV vaccination (P=0.13) or OPN × RV vaccination (P=0.33) 
was observed. The only significant effect is time (P<0.0001).  
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     Table A.4.  Effect of Dietary Treatment and Vaccination on Rotavirus-Specific Serum IgG.1,2,3 
 
 
 Day 7 Day 14 Day 21 Day 28 Day 35 
 
FF + RV 
 
290 ± 41 320 ± 46 567± 81 1620 ± 231 1870 ± 267 
 
OPN + RV 
 
300 ± 46 349 ± 54 867 ± 133 1453 ± 224 2136  ± 329 
 
FF + NV 
 
275 ± 39 104 ±15 443 ± 63 549 ±78 1356 ± 194 
 
OPN + NV 
 
245 ± 33 126 ± 17 492 ± 68 919 ± 130 1428 ± 202 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Data are expressed as mean ± SEM 
2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; NV, non-vaccinated; V, vaccinated with Rotarix® 
3 In the complete model, no effect of OPN (P=0.82), RV vaccination (P=0.35) or OPN × RV vaccination (P=0.99) 
was observed. The only significant effect is time (P<0.0001).  
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    Table A.5.  Effect of Dietary Treatment and Vaccination on Rotavirus-Specific Serum IgA.1,2,3 
 
 
 Day 7 Day 14 Day 21 Day 28 Day 35 
 
FF + RV 
 
0 
 
47 ± 8 
 
406 ± 68 829 ± 138 673 ± 112 
 
OPN + RV 
 
0 
 
42 ± 7 
 
561 ± 89 844 ± 134 840 ± 131 
 
FF + NV 
 
0 0 402 ± 62 603 ± 92 523 ± 80 
 
OPN + NV 
 
0 0 545 ± 84 582 ± 89 571 ± 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Data are expressed as mean ± SEM 
2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; NV, non-vaccinated; V, vaccinated with Rotarix® 
3 In the complete model, no effect of OPN (P=0.76), RV vaccination (P=0.54) or OPN × RV vaccination (P=0.92) 
was observed. The only significant effect is time (P=0.0004).  
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    Table A.6. Effect of Dietary Treatment and Vaccination on Rotavirus-Specific Serum IgM.1,2,3 
 
 
 Day 7 Day 14 Day 21 Day 28 Day 35 
 
FF + RV 
 
0 5117 ± 852 8355 ± 1390 3922 ± 653 1273 ± 212 
 
OPN + RV 
 
 
3 ± 0.7 
 
5139 ± 790 7983 ± 1228 4254 ± 654 1569 ± 241 
 
FF + NV 
 
0 608 ± 103 3941 ± 668 3186 ± 540 1059 ± 179 
 
OPN + NV 
 
0 808 ± 136 4136 ± 701 1108 ±187 853 ± 144 
 
 
 
1 Data are expressed as mean ± SEM 
2 Abbreviations:  FF, formula-fed; OPN, formula with OPN; NV, non-vaccinated; V, vaccinated with Rotarix® 
3 In the complete model, no effect of OPN (P=0.98), RV vaccination (P=0.04) or OPN × RV vaccination 
(P=0.56) was observed. The only significant effect is time (P<0.0001).  
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